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Summary 
 
In healthy individuals the intestinal microbiota, a complex microbial ecosystem, and 
the host maintain a mutually beneficial relationship. The microbiota contributes 
significantly to fundamental physiological functions of the host such as the 
degradation of complex food ingredients, colonization resistance against pathogenic 
bacteria and the development of host immune system. A balanced composition of the 
microbiota is crucial to provide its beneficial functions to the host’s health. In contrast, 
alterations at the overall phylum level, the addition or lack of specific members or of 
particular functions of the gut microbiota have been associated to worse or recover 
disease outcomes. Specifically, studies have demonstrated that alteration in the 
composition of gut microbiota can dramatically affect host immunity and are 
frequently associated to common gastrointestinal diseases. Therefore it is essential 
to investigate and identify the key players that tip the balance between pathogenic or 
homeostatic host-microbiota interactions to eventually develop novel microbiome-
centered therapeutics to modulate inflammatory diseases.  
 
Here we demonstrated that alterations in gut microbial communities are able to 
directly enhance the disease severity in a mouse model of human inflammatory 
bowel disease (IBD). Specifically, we unveiled that distinct microbial communities 
utilized opposing arms of host immunity to promote disease severity. While one 
community required microbiota-specific CD4+ T cell responses, another community 
triggered severe intestinal inflammation even in the absence of adaptive immunity. 
Intriguingly, an overexpansion in the Proteobacteria over the Firmicutes phylum was 
associated to pathogenic CD4+ T cell response.  
 
Next, we elucidated beneficial CD4+ T cell responses driven by specific commensals 
during intestinal inflammation. Specifcally, we explored a previously reported 
immunomodulatory bacteria, segmented filamentous bacteria (SFB) and its effect on 
Salmonella induced gastroenteritis. While this bacterium is known to induce 
proinflammatory cells, SFB specific CD4+ T cells served as “innate-like” source of 
antibacterial cytokines rapidly after infection. Importantly, SFB colonized mice 
displayed reduced pathogen invasion in the cecum suggesting that modulation of 
CD4 T cells by SFB is associated with improved immune defense. 
 
Together our studies demonstrate that the intestinal microbiota can directly influence 
host immunity to exert both pathogenic and beneficial disease outcome. Further 
studies are needed to explore specific interactions among distinct microbial members 
and host factors to drive different disease pathogenicity. Elucidation of similar 
microbiota induced effects in human may help to develop personalized therapies. 
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Zusammenfassung 
Die intestinale Mikrobiota ist ein komplexes mikrobielles Ökosystem, das mit dem Wirt in 
einer gegenseitigen positiven Wechselwirkung steht. Die Mikrobiota spielt eine 
entscheidende Rolle in der Physiologie des Wirts; insbesondere in der 
Nahrungszersetzung, der Kolonisierungsresistenz gegenüber pathogenen Bakterien und 
der Entwicklung des Immunsystems. Eine günstige Zusammensetzung der Mikrobiota ist 
wichtig, um nützlichen Funktionen für die Gesundheit des Wirts zu garantieren. Im 
Gegensatz dazu werden mikrobielle Veränderungen und die Zugabe oder das Fehlen 
spezifischer Mitglieder bzw. bestimmter Funktionen der Darmmikrobiota mit einer 
Verschlechterung oder Verbesserung der Krankheit assoziiert. Studien haben gezeigt, 
dass eine Veränderung der Zusammensetzung in der Darmmikrobiota die Wirtsimmunität 
drastisch beeinflussen kann und häufig mit Magen-Darm-Erkrankungen assoziiert ist. 
Daher ist es von Bedeutung, die wichtigsten Akteure, die das Gleichgewicht zwischen 
pathogenen oder homöostatischen Wechselwirkungen mit der Mikrobiota beeinflussen 
können, zu identifizieren und zu untersuchen. Dies ist wichtig und vielversprechend, um 
letztendlich neue Mikrobiom-basierte Therapeutika zu entwickeln, die entzündliche 
Erkrankungen modulieren können. 
 
In dieser Dissertation konnte gezeigt werden, dass Veränderungen in der 
Darmmikrobiota in Mäusen einen direkten Einfluss auf die Schwere von chronisch-
entzündlichen Darmerkrankungen (CED) haben. Außerdem konnte nachgewiesen 
werden, dass verschiedene mikrobielle Gemeinschaften gegensätzliche Signale der 
Wirtsimmunität nutzten, um den Schweregrad der Krankheit zu regulieren. Während eine 
Gemeinschaft von Bakterien spezifische CD4+ T-Zellantworten benötigte, um eine 
schwerwiegende Darmentzündung auszulösen, konnten diese von einer anderen 
Gemeinschaft auch in Abwesenheit einer adaptiven Immunantwort geschehen. Darüber 
hinaus war eine Überexpansion an Proteobakterien mit einer pathogenen CD4+ T-
Zellreaktion assoziiert. 
 
Zudem wurden nützliche CD4+ T-Zellantworten entdeckt, die durch spezifische 
kommensale Bakterien während der Darmentzündung angeregt werden. Insbesondere 
wurde die Wirkung eines zuvor beschriebenen immunregulierenden Bakteriums, das 
„Segmentierte filamentöse Bakterium“ (SFB), auf Salmonella-induzierte Gastroenteritis 
untersucht. Es war bereits bekannt, dass dieses Bakterium pro-inflammatorische Zellen 
induziert, SFB-spezifische CD4+-T-Zellen wurden hier als neue "angeborene“ Quelle von 
schnell induzierten antibakteriellen Zytokinen während der Infektion identifiziert. SFB-
kolonisierte Mäuse zeigten eine reduzierte Pathogeninvasion im Cecum zeigten, was. 
Daraufhin deutet, dass die Modulation von CD4-T-Zellen durch SFB mit einer 
verbesserten Immunabwehr verbunden ist. 
 
Zusammenfassend konnten gezeigt werden, dass die intestinale Mikrobiota die 
Wirtsimmunität direkt beeinflussen kann und somit Krankheitsverläufe verbessert oder 
verschlechtert. Weitere Untersuchungen sind erforderlich, um spezifische 
Wechselwirkungen zwischen verschiedenen mikrobiellen Mitgliedern und Faktoren des 
Wirts zu erforschen, um eine unterschiedliche Krankheitspathogenität zu bewirken. Die 
Aufklärung ähnlicher Mikrobiota-induzierter Effekte bei Menschen kann dazu beitragen, 
personalisierte Therapien zu entwickeln. 
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CHAPTER 1 
 
General Introduction 
 
The Gastrointestinal (GI) tract of all vertebrates harbors diverse communities 
of microorganisms consisting of large numbers of bacteria, fungi, parasites 
and viruses commonly known as gut microbiota. In healthy individuals the 
intestinal microbiota and host maintain a symbiotic balance where the 
microbiota contributes to diverse physiological processes in the host and the 
host in turn provides a nutrient rich niche for the microbes. In recent years our 
knowledge about human gut microbiome have improved significantly and 
studies have discovered profound effect of the composition of the intestinal 
microbiota in human health. Substantial advances in culture independent 
sequencing based techniques have allowed insights into the compositional 
diversity of the human gut microbiota as well as contributions of diet, 
geography and individual variability 1–3.  
 
Alterations in the gut microbial composition can result from changes in host 
physiology due to environmental challenges and/or genetic defects. 
Numerous studies have associated changes in the gut microbiota composition 
with various disorders ranging from gastrointestinal diseases to systemic 
diseases such as obesity, allergy and neurodegeneration. Based on different 
disease models both beneficial and harmful effects of microbiota on disease 
outcome have been described. However, some important aspects of the 
influence of the intestinal microbiota to host pathophysiology still remains to 
be elucidated: 1. Can alteration in gut microbiota composition or a specific 
member of the commensal bacteria directly affect inflammatory disorder? 2. 
What specific host immune response mediated by the intestinal microbiota 
can result in beneficial or harmful outcome in different disease systems? 
Investigating these important aspects of the microbiota study can help to 
target microbiota or microbiota induced pathways to advance personalized 
treatment towards microbiota-mediated diseases. 
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1.1 Microbiota-host interaction in the gastrointestinal tract 
during homeostasis 
 
Starting with birth, the mucosal surfaces of the mammalian GI tract face a 
continuous challenge of constant exposure to complex microbial communities. 
More than 100 trillion microorganisms, comprising over 500 species of 
bacteria harbor an adult human. In healthy individuals, Gram-negative 
Proteobacteria and Bacteroidetes, and Gram-positive Firmicutes, are the 
major phyla among intestinal eubacteria, whereas methanogens are the 
predominant intestinal archaea.  
 
Figure 1.1 Distribution of microbiota and metabolites throughout the intestine. 
The numbers and diversity of the gut microbiota increase towards the distal GI tract, ranging 
from 102-103/ml in stomach upto 1012/ml in colon. Availability of different sources of nutrients 
vary greatly throughout the GI tract, i.e. a decrease in the level of vitamin A and an increase 
in short chain fatty acids (SCFAs) level can be observed towards distal part of the GI tract. 
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Diversity and concentrations of colonized bacteria vary according to anatomic 
location as well as availability of nutrients and increases along with the distal 
part of the intestine (Figure 1.1). Large fractions of these intestinal bacteria 
are anaerobic and very difficult to grow under laboratory culturing conditions.  
However, recent advancement in sequencing techniques has allowed us not 
only to gain insight their detailed composition using 16S ribosomal RNA 
based sequencing, but also characterize their functionalities by analyzing the 
genomic composition using shot gun metagenome-sequencing.  
 
The primary function of gut microbiota is to enhance host digestive efficiency. 
Fermentation of complex polysaccharides and oligosaccharides by colonic 
microorganisms results in the synthesis of SCFAs such as butyrate, 
propionate and acetate, which are rich sources of energy for the host 4. Gut 
microbiota also contributes to lipid metabolism and hydrolysis. Protein 
metabolizing machinery that function via microbial proteinases and peptidases 
in tandem with human proteinases are also enriched in the gut microbiota. 
Another major metabolic function of the microbiota is synthesis of vitamin K 
and several components of the vitamin B2 family. Distinct members, i.e. 
Bacteroides intestinalis, B. fragilis, Escherichia coli have the capacity to 
dehydrate and deconjugate the primary bile acids and convert them into 
secondary bile acids in human colon 5. Besides significant contributions to 
host metabolic functions, the gut microbiota also plays critical roles in 
educating the host immune system, which will be discussed later in detail.  
 
1.1.1 Mucosal immune system maintaining microbial balance 
 
In past models, all microorganisms were viewed as potential pathogens that 
could cause and propagate infectious diseases and, as a field, immunology 
was built around the paradigm that to preserve homeostasis the host immune 
system should recognize and eliminate these intruders (non-self) while 
tolerating self-molecules. However, animal and plant species have shown 
persistent association with obligate and facultative symbionts, which requires 
refining our idea of beneficial cooperative relationships between bacteria and 
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their eukaryotic hosts. Therefore, a new paradigm was proposed suggesting 
that the immune system has evolved to accommodate colonization by 
symbiotic bacterial communities of increasing complexity while retaining the 
capacity to fight pathogens. Development of host immune factors to maintain 
homeostatic microbial load in the GI tract has been extensively studied and 
some of the important host factors will be discussed below. 
 
Bacteria-host epithelium contact minimization:  
Minimization of the contact between intestinal bacteria to its host epithelium is 
one of the first stages to maintain microbial balance in the gut (Figure 2A). 
The mucus layer on top of the host epithelium specifically in colon comprises 
a variety of mucin glycoproteins secreted by goblet cells, forming two 
structurally distinct layer, one dense inner layer devoid of bacteria and the 
other loose outer layer where commensal bacteria can reside 6. Epithelial 
barrier also protects host from huge bacterial load by epithelial cells secreted 
antimicrobial proteins (AMP). Most of these antimicrobial proteins i.e. 
defensins, cathelicidins, C-type lectins kill bacteria directly through enzymatic 
attack or disruption of bacterial inner membrane and some subset including 
lipocalin 1 results deprivation of essential metals like iron for the bacteria 7. 
Secretory immunoglobulin A (IgA) plays also a significant role to limit bacterial 
association with the intestinal epithelial cell surface 8. Transcytosed IgA 
secreted from plasma cells binds to bacteria on the luminal side limiting 
epithelial association of bacteria and preventing bacterial penetration of host 
tissues 9.  
 
Controlling of penetrated bacteria via immune responses: 
Even after a strict control at the epithelial barrier some intestinal bacteria can 
penetrate to mucosal tissue where distinctive immune mechanisms play role 
to detect and kill penetrated bacteria (Figure 2A). Lamina propria 
macrophages provide such mechanism via phagocytosis of bacteria followed 
by killing via AMPs and reactive oxygen species (ROS) 10. In addition, CD4+ T 
cells specifically Foxp3+ regulatory T cells (Tregs) are an essential 
component to maintain tolerance towards environmental antigens including 
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commensal bacteria. Tregs can control the balance of bacterially induced 
effector cells like Th1 cells and in addition regulatory cytokines secreted by 
Tregs such as IL-10 and TGF-β are also equally important to maintain 
intestinal homeostasis. Notably, spontaneous inflammation has been 
observed in mice deficient in IL-10 11 or TGF-β 12. Similarly, Th17 cells also 
have been reported to regulate normal intestinal microbiota. Some other 
subsets of host immune system i.e. intraepithelial CD8aa+ T cells and natural 
killer (NK) cells are also being studied to associate with maintaining host-
microbiota balance. These studies together strongly suggest that numerous 
host factors are engaged to strictly regulate the microbial load in the GI 
mucosa and breaches in such regulatory mechanisms may allow microbial 
antigens to penetrate both locally and systemically and affect host health. 
 
 
Figure 1.2 Host-microbiota interaction in the intestine during homeostasis. 
A) Host immune system maintains the microbial load at the mucosal surface of the intestine. 
Inner thick mucus layer halts bacterial entry, AMPs produced by different cell subsets in the 
epithelium kills penetrated bacteria and different host immune cells provide protection via 
sIgA secretion, phagocytosis and Treg generation.  
B) Immune system development in host is strongly modulated by gut microbiota. Intestinal 
bacteria helps maturation of isolated lymphoid follicles (ILFs), generation of IgA secreting 
plasma cells. Some specific members of bacteria helps to develop different subsets of 
immune cells, i.e. SFB mediated Th17, Clostridium spp. mediated Treg development. 
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1.1.2 Intestinal bacteria modulating mucosal immunity and functionality 
 
As important it is for the host to maintain commensal load to the mucosal 
surface, beneficial functions provided by balanced microbiota are similarly 
important for proper development of host mucosal immunity (Figure 2B). 
Continuous exposure to different bacteria throughout life provides benefits 
from lymphoid tissue development to maturation or educating immune 
system. Studies performed in germ free (GF) animals have demonstrated 
influence of microbiota to maintain host immunity, however, only a handful 
studies could probe direct association of specific microbial species involved in 
modulating particular host immunity.  
Development of gut associate lymphoid tissue (GALT), an important immune 
structure for antigen uptake and presentation, significantly regulated by 
intestinal bacteria. Although in fetus lymphoid tissue inducer (LTi) cells 
promote development of Peyer’s patches, the maturation of isolated lymphoid 
follicles (ILFs) and crypt patches requires stimulation by the gut microbiota 
13,14. 
Besides morphological tissue development of immune system, gut microbiota 
also plays significant role for the development and accumulation of distinct 
subsets of leukocytes both locally and systemically. Intestinal bacteria driven 
signals have regulatory influences on intestinal antigen presenting cells 
(APCs). Dendritic cell (DC) populations in the intestine are reduced in GF 
animals and has shown to recruited upon monoassociation with E. coli 15,16. 
While numbers of monocytes/macrophage were normal in intestinal tissue, 
systemic monocyte/macrophage numbers were reduced in animals reared 
under GF conditions and colonization with Lactobacillus acidophilus and L. 
reuteri could recover such defect 17. Moreover, some studies have suggested 
that microbiota is important for proper differentiation of innate lymphoid cells 
(ILCs) to produce IL-22 18,19. 
Contributions of the gut microbiota and specific members to modulate host 
adaptive immunity have been studied extensively. Gut-specific B cell 
responses are intimately related to microbiota. In the intestine plasma cells 
derived from B cells produces polymeric IgA at high concentrations, which is 
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then transported and released into the intestinal lumen as secretory IgA (sIgA) 
20. In GF mice, numbers of IgA-producing cells in the intestine are significantly 
reduced 21. One important mechanism thought to influence IgA production is 
bacterial recognition through MYD88 in follicular DCs 22. Notably, DC 
recognition of flagellin derived from commensal bacteria promotes retinoic 
acid synthesis facilitating differentiation of IgA producing B cells 23,24. 
Furthermore, in lamina propria DCs, intestinal bacteria enhance expression of 
factors that are involved in induction of IgA+ B cells, i.e. tumor necrosis factor 
(TNF), inducible nitric oxide synthase (iNOS), B cell activating factor (BAFF) 
and a proliferation-inducing ligand (APRIL) 25,26. 
Adaptive T lymphocytes specifically CD4+ helper T (Th) cells are crucial for 
host immune responses both during health and diseases. Distinct lineages of 
Th subsets with potentiality of different immunoregulatory cytokine secretion 
are closely regulated by the gut microbiota. One of the best examples is the 
generation of intestinal Th17 cells, a subset of activated CD4+ T cells 
characterized by production of IL-17A, IL-17F and IL-22 27, by particular 
species of Clostridia-related bacteria, called segmented filamentous bacteria 
(SFB) in mice 28–30. Adhesion of SFB to the intestinal epithelial cell (IEC) is 
indispensible for Th17 cell development 31. Although SFB was not observed in 
human, a mixture of 20 bacterial strains isolated from human patients, able to 
induce Th17 cells in mouse colon, also demonstrated IEC-adhesive 
characteristics 31. SFB colonization results in robust IL-22 secretion by type 3 
ILCs that induces serum amyloid A protein (SAA) production by IECs in a 
Stat3-dependent manner 32. The aforementioned study also showed that early 
after SFB colonization RORγt+ T cells were induced in mesenteric lymph 
nodes followed by distribution across different parts of GI tract and continuous 
IL-17A production however was only restricted in ileum. 
Intestinal bacteria also regulate another subsets of CD4+ Th cells, Foxp3+ 
Tregs that are strictly required to maintain gut homeostasis. Peripherally 
derived Treg cells are greatly decreased in the colonic lamina propria of GF 
mice 33,34. Several studies have shown colonization of GF mice with distinct 
groups of commensal bacteria can recover accumulation of IL-10 producing 
Treg cells in colon, i.e. a mixture of 46 Clostridium spp. cluster IV and XIVa 
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strains; altered Schaedler flora (ASF), a cocktail of eight defined commensal 
bacteria; or the human commensal bacterium Bacteroides fragilis 33–35. 
However, the mechanism behind bacterially induced Treg development still 
remains to be elucidated.  
Finally the microbiota also contributes to the proliferation and function of 
different other T cell subsets. For example, in GF mice numbers of TCRαβ+ 
intra epithelial lymphocytes (IELs) are reduced and colonization with SFB and 
Clostridium spp. induces accumulation of this IEL subset in small and larger 
intestines respectively 36. Moreover, intestinal bacteria have been shown to 
particularly expand IL-1R1 expressing IL-17 producing γδ T cells in 
conventionally raised mice 37. 
 
1.2 Host-microbiota interplay during GI inflammation 
 
Gastrointestinal diseases are a substantial burden and responsible for 
approximately eight million deaths per year worldwide and one million deaths 
each year across Europe. Diarrheal disease is the second leading cause of 
death among child <5 years old, with the majority of these deaths occurring in 
Africa. Gastrointestinal-related cancers are responsible for nearly 40% of all 
cancer-related deaths with a toll of nearly 3 million deaths per year estimated 
in 2008. The incidence and prevalence of many GI diseases are highest 
amongst the very young and the elderly also causing significant morbidity and 
healthcare costs. GI tract encounter different forms of challenges though food, 
environment, habitat resulting different forms of infectious and autoimmune 
diseases. Many aspects of digestive diseases are still poorly understood e.g. 
the involvement of the gut microbiota. In the following I will discuss two very 
common forms of autoimmune and infectious disease of the GI tract and 
specifically the interplay of the host and the intestinal microbiota during such 
inflammatory disorders. 
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1.2.1 Inflammatory bowel diseases  
 
Inflammatory bowel disease (IBD) is characterized by chronic relapsing 
inflammatory disorders of small and/or large intestine resulting in recurrent 
diarrhea and abdominal pain. There are two main clinicopathological subtypes 
of IBD- Crohn’s disease (CD) and ulcerative colitis (UC). CD can affect any 
part of the GI tract most commonly the terminal ileum and colon and is 
microscopically characterized by transmural inflammation, thickening of 
submucosa, fissuring ulceration and granuloma formation in a discontinuous 
pattern. UC on the other hand is restricted to colon and rectal area and forms 
continuous superficial inflammatory changes in the mucosa and submucosa 
with cryptitis and crypt abscesses 38. For IBD development family history is an 
important risk factor, with a higher incidence in early adult life. A high 
prevalence of IBD is observed in industrialized countries, with the highest 
reported incidences in northern Europe and North America. An estimated 2.5-
3 million of Europeans suffers from IBD with a direct healthcare cost of 4.6 - 
5.6 billion Euros per year. A direct etiology for IBD development is still 
unknown. However, association of several risk factors have been studied and 
reporter. Different environmental factors, such as smoking, diet, drugs, 
geography, social stress, and psychological element have been reported as 
considerable risk factors 39. However, in most incidences IBD is thought to 
occur in genetically susceptible individuals by an abnormal immune response 
against the microorganisms of the intestinal flora. Therefore, more and more 
careful investigations are being carried out to understand the interplay 
between host immunity and microbiota in the initiation of IBD. Common IBD 
therapies include interventions on life-style habits and medical and surgical 
treatments, where medical management involves use of corticosteroids, 
immunosuppressant agents and biological therapies 38. However, recent 
studies are proposing towards targeting microbiota and microbiota-mediated 
host immune pathways to control IBD.  
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Host immune factors responsible for IBD development: 
Genome-wide association studies (GWAS) that identify single nucleotide 
polymorphisms (SNPs) have contributed significantly to identify host genetic 
factors to IBD. Until now 163 hosts gene loci associated to IBD were identified 
40,41. Gene loci observed from GWAS and other coherent studies have 
highlighted a significant involvement of distinct innate and adaptive immune 
pathways to develop IBD. While most studies in the last two decades have 
focused on the role of abnormal adaptive immune responses to IBD 
development, recent studies have found that many IBD patients display 
dysfunctional mucosal innate immunity.  
Innate immunity provides a first line of defense, e.g. the epithelial barrier 
provides a first physical barrier towards bacterial and food antigens. In 
patients with CD and UC, a defective epithelial barrier and an increased 
intestinal permeability have long been observed 42. Particularly in UC patients 
several SNPs, i.e. in HNF4A, CDH1, LAMB1 and GNA12, suggesting that 
epithelial barrier defects are found to be associated to disease susceptibility 
43,44. In CD patients on the other hand a defective antimicrobial peptide 
expression have been observed. Compared to UC, inflamed colon of CD 
patients showed reduced induction of β-defensins HBD2, HBD3 and HBD4 45. 
Defects in microbial antigen sensing by innate immune cells, such as 
macrophages and DCs are strongly associated to IBD formation. Different 
pattern recognition receptors (PRRs) of host immune cells recognize microbial 
antigens. PRRs include trans-membrane Toll-like receptors (TLRs) and 
intracytoplasmic nucleotide-binding oligomerization domain (NOD)-like 
receptors (NLRs). NOD2 was the first susceptibility gene identified to confer 
increased risk to CD 46,47. An important innate immune process of controlling 
intracellular bacterial invasion is autophagy. Mutations in genes involved in 
autophagy, such as, ATG16L1 and IRGM have been associated to CD 48,49. 
Moreover, a key cytokine, IL-23, orchestrating the crosstalk between innate 
and adaptive immunity plays a central role to regulate early immune 
responses to microbes. SNPs in IL23R gene that encodes specific subunit of 
IL23 receptor have been identified in different independent cohorts of IBD 
patients 50. Some other IBD risk variant genes such as STAT3 and JAK2, 
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involved in IL-23 signal transduction are also shown to be associated with IBD 
51. Neutrophils, short-lived innate immune cells have ability to destroy 
extracellular and intracellular invading pathogens. Accumulation of three fold 
increased numbers of activated neutrophils have been observed in the blood 
of UC patients 52. Blockade of neutrophil significantly attenuated inflammation 
in murine experimental colitis 53,54. 
Adaptive immune system is highly specific and provides long lasting immunity. 
Dysregulation of adaptive immune cells, specifically T cell responses resulting 
excessive release of different pro-inflammatory cytokines and chemokines 
have been associated to CD and UC. Classically, it has been considered that 
CD is characterized by Th1 immune responses, while UC is mediated by Th2 
responses 55. Abnormal Th1 immune responses, triggered by release of IL-18 
and IL-12, is thought to cause intestinal inflammation in CD 56,57. It has also 
been demonstrated that activated T cells from CD mucosa release more IFN-γ 
than T cells from UC patients or controls, whereas UC patients produce more 
IL-5 58. Also NK T cells in UC patients release higher amounts of Th2 cytokine 
IL-13 than from controls or CD patients 59,60. Notably, tumor necrotic factor 
(TNF)-α, a pro-inflammatory cytokine secreted by Th1 and also by mucosal 
macrophages, plays a crucial role in IBD pathogenesis. Impressive results 
have been observed in clinical trials with biologic agents targeting TNF- α 61. 
Furthermore, Th17 cells, another important T cell subsets, are induced by a 
combination of IL-6 and transforming growth factor (TGF)-β. High transcript 
levels of IL-17A secreted by Th17 cells have been detected in CD and UC 
mucosa in comparison to normal gut, and also overexpression of IL-17A by 
immunohistochemistry has been observed in lamina propria of IBD patients 
62,63. Additionally, IL-21, an IL-2 related cytokine is upregulated in inflamed 
mucosa of IBD patients and is produced by Th17 cells 64,65. Distinct T cell 
subsets play crucial role to maintain homeostatic balance of host immune 
system. Foxp3 expressing regulatory T cells are important to maintain gut 
homeostasis and to suppress abnormal immune responses by producing anti-
inflammatory cytokines IL-10 and TGF- β. Tregs are depleted in peripheral 
blood of active IBD patients compared to quiescent IBD patients and controls 
66. Besides T-cell dependent influence of IBD development, B-cell defects 
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leading to colitis have also been demonstrated in some experimental studies. 
Moreover, recent GWAS of deficiency in IgA, produced by B cells, showed 
genes also implicated in IBD, i.e. ORMDL3, REL and PTPN22 67. Together 
these aforementioned studies strongly support the involvement of host 
immune system for IBD development. However, targeting these host immune 
factors to ameliorate IBD shows variable outcomes and still needs to be 
studied in detail what other factors are interplaying to develop such complex 
pathology.  
 
Contribution of gut microbiota to IBD: 
Many studies have demonstrated a correlation between alterations in the gut 
microbiota and IBD development. Notably, studies performed in animal colitis 
models under GF and other gnotobiotic microbiota conditions have shown a 
direct influence of certain microbial species to cause enhancement of colitis 
severity by modulating host immune and/or metabolic pathways (Figure 3A). 
However, which specific intestinal bacteria directly regulate development and 
progression of IBD in human patients still remains to be investigated. 
Compared to the healthy intestine, an overall decrease in resident Firmicutes 
and over-representation of certain Bacteroides and/or Proteobacteria have 
been observed in IBD patients. Clostridium clusters XIVa and IV among 
Firmicutes, are largely underrepresented in IBD patients 68–70. A significant 
reduction of Faecalibacterium prausnitzii abundance is observed in patients 
with active IBD compared to those in remission 71 and also in patients with 
recurrent IBD 72 suggesting a anti-inflammatory role of F. prausnitzii. 
Presence of F. prausnitzii in vitro resulted in production of anti-inflammatory 
IL-10 and inhibited secretion of pro-inflammatory IL-12 and IFN-γ in human 
PBMC 72. F. prausnitzii is able to metabolize diet-derived polysaccharides and 
other substrates to produce butyrate 73,74, a major source of energy for colonic 
epithelial cells and mucosal health. Microbiota-produced butyrate has also 
been shown to induce Treg development 75,76. Abundances of other butyrate-
producing bacteria, i.e. Roseburia hominis and Eubacterium rectale are 
similarly reduced in IBD patients 77,78. Moreover reduction in Bifidobacterium 
adolescentis, a folate-producing bacterium was observed in IBD patients 
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68,70,79. Folate is known to enhance Treg survival and thereby diminish 
intestinal inflammation 80. Expansion of Proteobacteria phylum in IBD patients 
was revealed by several studies 81–83. Of the Proteobacteria, one of the most 
studied and reported group is Gammaproteobacteria, specifically, Escherichia 
coli. Pathogenic E.coli strains accumulate in intestinal stool and mucosa of 
IBD patients, especially CD 84–86. Adherent-invasive E.coli (AIEC) strains from 
IBD patient have been isolated and shown to adhere and invade intestinal 
epithelial cells and colonize the ileal mucosa of CD 87. AIEC also replicate in 
macrophages and stimulate TNF-α production from macrophages. Certain 
Gammaproteobacteria such as, Klebsiella spp., Pseudomonas spp., and 
Salmonella spp. have also been implicated in IBD 88,89. Deltaproteobacteria 
comprise sulfate-reducing bacteria and the abundances of these bacteria are 
also increased in IBD patients 90–92. Sulfate-reducing commensal Bilophila 
wadsworthia increases due to excessive dietary taurocholic acid and can 
cause Th1 mediated colonic inflammation in IL-10-/- mice 93. Moreover, 
abundances of some Epsilonproteobacteria i.e. Campylobacter concisus and 
Campylobacter jejuni are higher in intestinal biopsies or fecal samples of IBD 
patients 94,95. These Campylobacter spp. attach to intestinal epithelial cells to 
secret IL-8 and IL-8 recruits neutrophils, DCs and macrophages. These 
recruited cells then interact with internalized bacteria resulting secretion of 
pro-inflammatory cytokines, IL-1, IL-6, IL-12 and TNF-α 94,96,97. Taken 
together, both presence and absence of distinct gut commensals is positively 
correlated to induce intestinal inflammation. It is therefore important to assess 
whether these commensals can induce distinct pathway to result similar 
inflammatory outcomes. 
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Figure 1.3 Role of gut microbiota during gastrointestinal inflammation. 
A) Studies have demonstrated that the gut microbiota contribute to IBD development. 
Decrease in Faecalibacterium sp. or other butyrate and folate producing bacteria result in 
decrease of regulatory T cells thereby enhance colitis development. Increase in members of 
Proteobacteria result in increased production of proinflammatory cytokines i.e. IL-6, IL-12, 
TNF-α etc. by Th1 and/or Th17 cells, which leads to formation of chronic inflammation. B) 
During Salmonella induced gastroenteritis gut microbiota provides colonization resistance via 
different mechanisms. SCFAs and butyrate produced by intestinal bacteria control Salmonella 
invasion. Microbiota induced development of phagocytic immune cells and AMP secretion by 
paneth cells can act on pathogen killing. Commensal protozoa Tritrichomonas musculis 
promotes IL-18 secretion followed by generation of Th1 and Th17 immunity against 
Salmonella pathogen to provide protection.  
 
1.2.2 Salmonella induced intestinal inflammation  
 
Similar to IBD, also during infectious diseases in the GI tract host immunity 
and the microbiota act in concert promoting intestinal inflammation. Infections 
caused by Salmonella spp. result both intestinal and systemic diseases in 
human and animal hosts and are crucial public health priority worldwide 98–100. 
Salmonella spp. are Gram-negative facultative intracellular pathogens 
belonging to the family Enterobacteriaceae. Depending on bacterial serovar 
and underlying host susceptibility Salmonella spp. cause different forms of 
clinical diseases 101. Three distinct categories of Salmonella infections have 
been described:  
i) Salmonella gastroenteritis, a localized intestinal infection, mainly 
results from ingestion of contaminated food products 102,103. An 
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approximate of 30-50% of food-borne infections is attributed to 
Salmonella serovars in the USA 104,105. Common symptoms include 
fever, diarrhea and cramping, however, most healthy individuals 
recover without treatment within 4-7 days. 
ii) Typhoid fever, a systemic Salmonella infection of healthy host, 
mainly caused by Salmonella enterica serovars Typhi and 
Paratyphi. An approximate of 21.7 million cases and 217,000 
deaths annually in developing nations are caused by Typhoid fever 
106. This disease is characterized by fever and hepatosplenomegaly 
with subsequent intestinal hemorrhage or perforation. A common 
way of prevention is vaccination. 
iii) Non-typhoidal Salmonellosis (NTS), a systemic infection of an 
immune-compromised host, results in fatal infections, which can be 
disseminated without gastrointestinal symptoms and can be 
transmitted by human-to-human contact. An increased association 
of NTS dissemination has been observed in HIV-infected individuals 
in Asia and Africa 107. 
Animal models, especially mouse models are being extensively used to 
understand pathogenesis, host response and involvement of the gut 
microbiota in Salmonella infections. Oral infection with S. Typhimurium in 
genetically susceptible mouse strains leads to spread of pathogen to systemic 
sites via gut-associated lymphoid tissues, which is similar to human typhoid 
fever 108. On the other hand, S. Typhimurium causes chronic infection of 
systemic organs in genetically resistant inbred mouse strains, which provides 
a useful animal model for persistent systemic infection 109. However, 
Salmonella cannot colonize the mouse intestine in all these typhoid fever 
models, which makes it difficult to study Salmonella driven enterocolitis in 
mouse models. This has been overcome by study demonstrated, a high-dose 
of oral streptomycin treatment of mice results efficient colonization of S. 
Typhimurium in large intestine and triggers severe acute inflammation of 
cecum and colon 110,111.  
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Host immune responses to Salmonella: 
The primary site of Salmonella infection are specialized microfold, or M cells 
in Peyer’s patches 112. M cells outside of Peyer’s patches and direct sampling 
of Salmonella by phagocytes in the lamina propria also contribute to the entry 
of the pathogen. Salmonella express a type-III secretion system, which is 
necessary for its M-cell invasion 113. Salmonella encounters various 
phagocyte populations after invasion into the host tissues. The pathogen can 
survive and replicate in macrophages after phagocytosis. However, by 
producing lysosomal enzymes, reactive oxygen intermediates, reactive 
nitrogen intermediates, and other antimicrobial peptides infected 
macrophages can be activated to kill or limit replication of Salmonella 114,115. 
Other massive inflammatory response, characterized by recruitment of innate 
immune cells, such as neutrophils, DCs, inflammatory monocytes and 
macrophages are also induced upon Salmonella invasion 116,117. Neutrophils 
have been reported to prevent dissemination of the bacteria 118 and 
inflammatory monocytes are important source of anti-microbial factors 117. 
Macrophages can also sense bacterial flagellin by NLRC4 to produce 
proinflammatory IL-18 via activation of caspase-1 119,120. DCs can present 
Salmonella antigen to naïve CD4 T cells to activate adaptive immune 
responses. 
Host adaptive immune responses play a significant role to prevent Salmonella 
infection. Different studies have shown the presence of Salmonella-specific 
early CD4 T cell responses after oral infection using T-cell receptor transgenic 
mice 121,122. Salmonella-specific CD4 T-cell activation occurs earliest around 
3-6h post infection within Peyer’s patches. The effector functions of distinct 
proinflammatory cytokine production by CD4 T cells during Salmonella 
infection is mainly acquisition of Th1 effector abilities via enhanced secretion 
of IFN-γ, TNF-α and IL-2 123,124. Appropriate activation of Th1 cells continue to 
expand and around 2-3 weeks after infection eventually comprise ~50% of 
total CD4 T cells in spleen 124. However, very little evidence suggests 
contribution of Th1 effector cells for bacterial clearance at early stage of 
infection. A recent study demonstrated alterations in the potency of regulatory 
T cells during Salmonella infection reduces Th1 activity and increases 
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bacterial growth 125. Th17-associated cytokines IL-17 and IL-22 play a major 
role during Salmonella infections. Accumulation of these cytokines occurs 
rapidly after oral infection with Salmonella 126,127. Increased bacterial loads in 
systemic tissues have also been observed in IL-17 deficient mice compared to 
wild-type mice 128. IL-23-dependent production of IL-22 was later found to 
contribute in-vivo bacterial clearance 129. A probable contribution of Th17 cells 
might be via neutrophil infiltration to intestinal tissues, since IL-17 deficient 
mice showed defective neutrophil recruitment abilities 130. Together, these 
studies indicate a strong involvement of Th17 cells and associated cytokines 
to provide protection against Salmonella-induced infections. 
 
Contribution of microbiota to Salmonella infection: 
The microbiota provides protection against enteric infection specifically in 
Salmonella induced gastroenteritis via different mechanisms (Figure 3B). 
Early studies have demonstrated that germ-free mice are more susceptible to 
infection than conventionally raised mice 131,132. It has been shown that 
Salmonella enterica serovar Typhimurium is capable of colonizing mice 
harboring low complexity microbiota, but is rapidly eradicated after co-housing 
with conventionally raised mice 133. The gut microbiota produces distinct 
metabolites such as short chain fatty acids (SCFAs). Butyrate down-regulates 
virulence genes, i.e. type III secretion system of Salmonella enterica and 
decreases its ability to invade or induce apoptosis of host cells in vitro 134. It 
also has been demonstrated that SCFAs and other organic acid such as 
lactate can reduce pH locally to a level below the optimum for Salmonella to 
grow 135,136. Moreover, several studies have revealed that commensal 
bacteria-driven MYD88-dependent and NOD2-dependent signals provoke 
intestinal paneth cell expression of different antimicrobial peptides, i.e. 
cryptdins, which limit S. Typhimurium penetration of epithelial barrier 137–139. 
Some members of the family Porphyromonadaceae have shown to protect S. 
Typhimurium-induced colitis via unknown mechanism, but do not provide 
direct colonization resistance 140. Bifidobacterium infantis has shown to 
increase the number of Tregs that reduced disease severity of S. 
Typhimurium infection 141. A recent study has revealed protection against 
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Salmonella via IL-18 mediated induction of Th1 and Th17 cells provided by 
gut commensal protozoa, Tritrichomonas musculis 142. Another recent study 
demonstrated induction of systemic IgG by groups of selective gut symbiotic 
gram-negative bacteria and elevated systemic IgG conferred protection 
against systemic Salmonella infection by directly coating bacteria to promote 
killing by phagocytes 143. These studies together strongly support that the 
intestinal microbiota play significant role to protect host against 
enteropathogen infections.  
 
1.3 Alteration in microbiota composition affects host 
pathophysiology 
 
The intestinal microbiota has constantly been exposed to different dietary and 
environmental pressure. While a stabilized and healthy microbiota 
composition is indispensible for host health, in recent years many of modern 
multifactorial diseases have been associated with the alteration in microbiota 
composition. Such altered composition of the gut microbiota is termed as 
dysbiosis and this affects both relative abundances of distinct groups of 
bacteria as well as the functionalities of the microbial community. Accordingly 
definition of dysbiosis can be explained as functional and compositional 
alterations of gut microbiota, which is driven by a set of host-related and 
environmental factors that perturb the microbiota by exceeding its resistance 
and resilience capabilities 144. However, among healthy individuals 
interindividual variability in microbial communities makes dysbiosis difficult to 
define. Similarly variability in the microbial composition is also present in the 
laboratory animals due to differences in vivaria and diet that can strongly 
influence experimental settings 145.  Dysbiosis can be categorized based on 
its characteristic features such as, bloom of certain pathobionts, loss of 
commensals, loss of diversity etc. Pathobionts are the otherwise under-
represented or potentially harmful bacteria in the GI tract and outgrowth of 
such pathobionts can enhance infection and inflammation, i.e. 
Enterobacteriaceae 146. Conversely, loss of residing beneficial commensals 
can be functionally important to enhance disease severity and restoration of 
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abolished bacteria or their functional product can eventually recover disease 
outcome. As an example, inflammation caused by Clostridium difficile has 
been shown to ameliorate by colonization with commensal Clostridium 
scindens 147. In addition, decrease in overall diversity of the intestinal bacteria 
has also been associated in dysbiosis context, i.e. IBD, dietary compostion, 
AIDS and type I diabetes 148–151.  
Dysbiosis can be caused by many different factors that influence microbiota 
composition. Notably numerous infections and inflammatory conditions have 
been associated to dybiosis formation. In mouse models, Citrobacter 
rodentium and Salmonella Typhimurium infection as well as chemically 
induced inflammation cause dysbiosis 152,153. Diet can result in both short-term 
and long-term effects on microbiota composition. Both low-fibre and high-fat 
diets have been shown to reduce microbial diversity in mice 149,154. Host 
genetics also play a crucial role in shaping intestinal microbiota 155. Finally 
transmission across generations and environmental transmission also play 
major role to reshape microbiota composition. 
Dysbiosis, once established, can affect both local and systemic host 
immunity. Alteration in microbiota composition is sensed by the host resulting 
in a different immune activation state and promoting disease conditions. For 
example, Porphyromonas gingivalis has been reported to disrupt homeostatic 
balance of oral commensal microbiota leading to inflammatory disease 
development 156. P. gingivalis can promote MYD88 degradation, followed by 
inhibition of antimicrobial responses 157. Dysbiotic microbiota modulated 
metabolites, such as taurine, histamine, spermine have been shown to 
influence NLRP6 signaling activity and modulate host ability to produce 
antimicrobial peptides 158. A similar study showed that transfer of dysbiotic 
community from IL-22 deficient mice reduces expression of IL-22-induced 
antimicrobial protein in wild type mice 159. Dysbiotic communities affecting 
host adaptive immunity have also been reported. Sutterella spp. are 
associated with low sIgA secretion and transfer of these microbiota to healthy 
host also confers low sIgA secretion and enhanced susceptibility to 
inflammation 160. Although numerous studies suggested strong influence of 
dysbiotic community to reshape host immune system, however it is still 
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unclear, whether dysbiosis can directly cause disease manifestation in healthy 
host.  
 
1.4 Mouse models and variables affecting host-microbiota 
interaction study 
 
Mouse models are crucial laboratory experimental systems in biomedical 
research to study microbial communities in mammalian host. Although 
significant differences exist between mice and humans in terms of anatomy, 
physiological responses and microbial composition, mice still represent a well-
characterized model to investigate universal responses. Maintenance under 
standardized conditions and manipulation of microbiota at will gives a unique 
opportunity to study how the microbiota affects host pathophysiology. Several 
different mouse models played major role in the field of microbiota study. 
Germ free (GF) mice completely lacking the microbiome have been used to 
study effect of different groups of microbiota in host immune system by 
monoassociation, conventionalization or transfer of distinct bacterial groups to 
GF mice 161. Isobiotic mouse lines exposed to only a defined set of bacteria 
are also attractive experimental system to analyze microbiome effects 162. The 
idea of using standardized minimal microbiota date back to beginning of mid 
1960’s when efforts were taken to reduce effects of different bacterial 
communities across experimental populations and still now “altered Schaedler 
flora” (ASF), a community of eight bacterial members is being widely used 163–
165. Another important tool for microbiota study is a humanized animal model. 
It has been demonstrated that mice humanized with different human donors 
result a similar microbiome composition and metabolic profile with 
preservation of individual-specific features 166. Many recent projects have 
focused to design minimal functional human microbial consortia that are easy 
to manipulate, maintain and interpret 167,168.  
Studies performed in mouse models to investigate different phenotypes 
specially influence of the gut microbiota on host often demonstrate lack of 
reproducibility. Several variables may play role in such discrepancies on 
observed phenotypes. One important variable is mouse strain background. 
Chapter 1 
 
 
 21 
Strain background contributes to many experimental phenotypes and also 
play a role in composition of microbiome 169. Many cases age dependent 
experimental phenotypes can also be observed 170. Other host factors, such 
as, gender, vertical transmission from parents can also affect microbiota-
mediated phenotypes. Several environmental factors affect significantly 
experimental phenotype, i.e. housing conditions, diet, handling of animal etc. 
Comparison for an experimental phenotype between mouse lines obtained 
from different housing conditions may significantly affect the result. Studies 
demonstrated that conventionally raised mice often harbor pathobionts like 
Helicobacteraceae, murine norovirus or protozoa etc. that can affect 
experimental phenotype.  Indeed IL-10-/- mice have shown to develop 
spontaneous colitis only under conventional housing conditions 171. Although 
many commercial vendors and academic institutions maintain pathogen free 
mouse facilities still many of them vary greatly among their microbiota 
composition 172 and in many cases harbor potential pathobionts like SFB, 
Prevotellaceae etc. Moreover, factors like lighting, temperature, bedding 
material also affect microbiota composition and mouse phenotypes. Food and 
water treatment and sterilization have shown to alter microbiome and very 
little is known about effect of different brands of standard animal feed that 
eventually can affect microbiota and microbiota-mediated phenotypes. 
Several attempts have taken to obtain proper solutions to deal with variables 
affecting microbiota and experimental phenotypes. One of the best solutions 
has been considered as to use littermate controls 145. Fecal transplantation or 
co-housing to equalize microbiota and its effect has also been demonstrated 
to transfer experimental phenotypes. Re-derivation of different gene-deficient 
mouse lines used in a same study by embryo transfer into a similar microbiota 
condition can also be considered to reduce some variability effects.  
 
1.5 Targeting microbiota as therapeutic intervention 
 
Host and microbiota acts in concert to maintain health state of an individual. 
Gut microbiota and microbiota modulated host pathways have long been 
considered to target as therapeutic intervention for diseases not only localized 
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in the intestine, but also involving systemic sites. Microbiota manipulation as a 
therapy has been carried out by use of probiotics, prebiotics, synbiotics, 
antibiotics and fecal microbiota transplantation (FMT). Many studies have 
demonstrated use of probiotics, live microoganisms, may confer health 
benefit. Most commonly used probiotics include Lactobacillus spp., 
Bifidobacterium spp., E.coli, Streptococcus spp. and some Enterococcus spp 
173. Mechanisms by which probiotics provide benefits involves, enhancement 
of GI barrier function, modulation of local and systemic immune responses, 
antagonizing pathogenic bacteria, production of beneficial metabolites etc. 
Providing selective ingredients known as prebiotics to change microbiota 
composition is another way to enhance host health. Examples of prebiotics 
are dietary fiber, non-starch polysaccharide and some oligosaccharides. A 
mixture of probiotics and prebiotics, commonly known as synbiotics, has also 
been applied to beneficially affect host. Common combinations include 
Bifidobacteria and fructooligosaccharides, Lactobacillus rhamnosus GG and 
inulin etc. Targeting microbiota by antibiotic has considered as therapeutic 
option. However, side effects of superinfection have discouraged use of 
antibiotic to manipulate microbiota. FMT consisting of infusion of fecal 
suspension from a healthy individual to gut of another one has shown to have 
better durable alteration of recipient’s gut microbiota compared to probiotics 
174. Suggested mechanisms for FMT include competition for nutrients, direct 
inhibition of pathogen growth and host immune modulation.  
Many clinical trial studies have been undertaken to observe impact of 
microbiota manipulation under disease conditions. Compared to Chron’s 
disease, microbiota manipulation has shown promising effect against 
ulcerative colitis. The strongest evidence derived from clinical trials conducted 
with VSL#3, a probiotic mixture containing 900 billion viable lyophilized 
bacteria represented by four strains of Lactobacilli, three of Bifidobacteria and 
one of Streptococcus salivaris 175,176. Kruis et al. reported equivalent 
percentages of efficacy and safety in maintaining remission in 162 UC 
patients giving probiotic E. coli Nissle 1917 compared to 165 patients 
receiving mesalazine 177. Successful efficacy of probiotics have also been 
reported against Clostridium difficile associated and other antibiotic-
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associated diarrhea 178. However, in the last years, FMT has been recognized 
as an promising treatment for recurrent C. difficile infection by remodulation of 
intestinal microbiota 179.  
As many studies demonstrate targeting microbiota can be a useful therapeutic 
intervention in many disease conditions, as valuable it becomes to understand 
the detailed mechanisms how microbiota and its effects to the host can be 
utilized to generate improved therapeutic strategies. Due to significant 
individual variations among human and their microbiota, more and more 
studies are also emphasizing to find out microbiotal biomarkers to enhance 
personalized therapies.  
 
1.6 Aims of this study 
 
An individual’s composition of the microbial communities in the GI tract 
reflects the dynamic development of host and microbes to ideally achieve a 
homeostatic, mutually beneficial state. But alterations in this homeostatic 
balance have been associated to many local and systemic disorders. 
However, it still remains to be elucidated whether altered gut microbiota or 
specific members of the intestinal commensal can directly influence host 
pathophysiology. Therefore the main focus of my PhD thesis is to investigate 
how distinct commensal bacterial communities or specific members of the 
microbiota can interact with different arms of the host immune system to 
directly influence the susceptibility to different inflammatory diseases in the GI 
tract. 
Studies investigating the effect of the microbiota in mouse model rely on 
specific tools, such as standardized housing conditions, defined disease 
models and mouse strains with identical genetic backgrounds. We have 
devised strategies to control such variables to investigate the aims of this 
study: 
1. The first aim of my thesis is to understand whether distinct microbial 
communities in the GI tract can directly influence disease susceptibility 
and whether different microbial communities trigger comparable 
intestinal pathologies via shared or distinct pathways. Here we applied 
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a mouse model of human ulcerative colitis using dextran sulfate 
sodium (DSS). To investigate the influence of distinct microbial 
communities we monitored susceptibility of DSS colitis to wild type 
mice obtained from different commercial vendors with similar genetic 
background and only differing in their microbiota composition. 
Furthermore different gene-deficient mouse lines rederived into a 
defined isobiotic microbiota that can easily be manipulated by 
cohousing will allow us to thoroughly monitor involvement of host 
immune system to mediate microbiota-induced colitis. We have also 
employed advanced techniques for characterizing distinct microbial 
communities and immunophenotyping of host harboring different 
microbiota.  
2. The second aim of my thesis is to evaluate whether specific member of 
the intestinal microbiota can modulate host immunity to influence the 
outcome of GI inflammatory disease. Here we studied, SFB, a 
previously reported intestinal microbial member having 
immunomodulatory effect. Studies demonstrated SFB could enhance 
different immune-mediated diseases by modulating host immune 
system. In this study we focused whether SFB through its in vivo host 
immunomodulatory effects can provide any benefit to the host during 
enterpathogen infection. We have used streptomycin mouse model of 
Salmonella Typhimurium induced gastroenteritis. Use of specific tool 
for cytokine and transcription factor knock-in reporter mice rederived 
into a defined isobiotic microbiota allowed us to monitor effect of SFB 
directly in vivo to modulate host immune cells producing different 
cytokines. Using such tool we could also characterize gene-signatures 
expressed in SFB imprinted immune cells.  
 
Together these investigations should enrich our knowledge about direct 
influence of gut microbiotal communities or specific member on modulating 
host immunity during homeostasis and inflammation. 
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CHAPTER 2 
 
Distinct microbial communities trigger colitis 
development upon damage to the intestinal barrier via 
innate or adaptive immune cells 
  
2.1 Summary 
 
Inflammatory bowel disease is a group of heterogeneous diseases 
characterized by chronic and relapsing mucosal inflammation. Alterations in 
microbiota composition have been proposed to contribute to disease 
development, but no uniform signatures have yet been identified. Here, we 
compare the ability of a diverse set of microbial communities to exacerbate 
intestinal inflammation after chemical damage to the intestinal barrier. 
Strikingly, genetically identical wild type mice differing only in their microbiota 
composition varied strongly in their colitis susceptibility. Transfer of distinct 
colitogenic communities in gene-deficient mice revealed that they triggered 
disease via opposing pathways either independent or dependent on adaptive 
immunity, specifically requiring antigen-specific CD4+ T cells. Our data 
provide evidence for the concept that microbial communities may alter 
disease susceptibility via different immune pathways despite eventually 
resulting in similar host pathology. This suggests a potential benefit for 
personalizing IBD therapies according to patient-specific microbiotal 
signatures.  
 
2.2 Introduction 
 
Inflammatory bowel disease (IBD) is a complex group of incurable 
inflammatory disorders comprising of Crohn’s disease (CD) and Ulcerative 
colitis (UC). These diseases develop in different areas of the gastrointestinal 
(GI) tract and are also characterized by different types of inflammatory 
responses 1,2. Although the etiopathogenesis of IBD development is not fully
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 understood, numerous studies support the hypothesis of IBD as a 
pathological immune response against microbial and environmental antigens 
in genetically predisposed individuals. The relative contribution of innate and 
adaptive immune cells and various cytokines to the development of IBD has 
been controversially debated 3. Nonetheless, an imbalanced interaction 
between the host immune system and gut microbiota is thought to play a 
pivotal role in disease manifestation and maintenance 4–6. 
In healthy individuals, microbiota and host maintain a symbiotic relationship, 
in which the microbiota provides benefits to the host by contributing to 
resistance against pathogens, to metabolic processes and to the proper 
development of the immune system 7. Notably, the composition of the 
microbiota can vary greatly among individuals being influenced by genetic 
predisposition and environmental factors, e.g. diet and use of antibiotics and 
other drugs 8,9. Numerous human disease conditions have been associated 
with imbalances in the composition of the gut microbiota, so-called dysbiosis, 
however, whether these changes contribute directly to the development of the 
disease or reflect an altered physiology of the host remains debated in many 
instances 7,10,11. Mouse models of human diseases have been vital to 
establish a causal role for the microbiota in the development of metabolic 
syndrome, behavioral abnormalities and infections. Moreover, in various 
mouse models of IBD the microbiota and in some cases specific members 
have been shown to influence disease outcome 12. Examples for IBD mouse 
models that lack disease development in the absence of any microbiota are 
the Il10-/- model of colitis and the TNFdeltaARE model of ileitis 13,14. Furthermore, 
disease development in these models is impaired or delayed in specific-
pathogen free (SPF) conditions compared to conventional housing conditions 
demonstrating that particular microbiota members or distinct communities only 
present in conventionally housed mice modulate disease onset. Specifically, 
Enterobacteriaceae in Tbet-/-Rag2-/- mice 15 as well as Bacteroides spp. 16, 
Helicobacter spp. 17 and Bilophila wadsworthia 18 in Il10-/- have been shown to 
enhance intestinal inflammation.  
The acute dextran sulfate sodium (DSS) colitis model of human UC is 
considered to be largely dependent on innate immunity 19. We previously 
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demonstrated that the dysbiotic microbiota of Nlrp6 inflammasome deficient 
mice has the ability to directly enhance DSS colitis severity, yet, the effector 
mechanism remained unknown 20. Notably, a recent study identified that 
specific metabolites of this dysbiotic community actively modulate innate 
immune signaling and subsequently the host-microbiota interface 21. 
Subsequently, similar dysbiotic communities with the ability to modulate the 
severity of DSS colitis have been described in other gene-deficient mice 22–24. 
However, it remains to be examined whether different colitogenic communities 
trigger intestinal pathologies via shared or distinct immune pathways. This 
knowledge could potentially explain the variable roles that have been 
suggested for various immune effectors and pathways for IBD pathogenesis. 
In the present study we have characterized the susceptibility of mouse lines 
differing only in their microbiota composition towards DSS colitis. Besides the 
dysbiotic community (DysM) from Nlrp6-/- mice, interestingly also certain but 
not all SPF communities demonstrated the abilities to cause severe intestinal 
inflammation in immunocompetent mice. While the colitogenic communities 
displayed differences in the relative abundance of specific bacterial families, 
they all shared similarly decreased ratio of Firmicutes to Bacteroides 
compared to communities causing only mild disease. Strikingly, mice 
displayed different inflammatory responses depending on their intestinal 
microbiota composition, either characterized by infiltration of neutrophils or the 
presence of proinflammatory CD4+ T cells. By utilizing gene-deficient mice 
and antibody-mediated depletion of T cell subsets we demonstrated that the 
DysM but not another colitogenic community depends on CD4+ T cells to 
exacerbate DSS colitis severity. Our data identifies that specific interactions 
between colitogenic communities and host immune pathways drive colitis 
development via distinct mechanisms. This highlights the potential to stratify 
patients by screening the microbiota and to develop microbiota-centered 
interventions for personalized IBD therapy. 
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2.3 Experimental procedures 
 
Mice: Wild type and all transgenic mice, Rag2-/-, Tcrbd-/-, muMT-/-, Tcrd-/-, 
OTII, CD4-/-, CD8-/-, IL-17AGFP IFN-γKatushka FoxP3RFP reporter mice used in the 
study were on C57BL/6N background and have been rederived into SPF-1 
microbiota by embryo transfer and bred at the specific pathogen free animal 
facilities of Helmholtz Centre for Infection Research (HZI). Nlrp6-/- mice were 
obtained from Yale University, USA and subsequently bred under 
conventional housing conditions at the HZI. Other donor microbiota for 
different composition were purchased from different commercial vendors 
(Janvier, Taconic, Harlan). Germ-free C57BL/6NTac mice were bred in 
isolators (Getinge) in the germ free facility of the HZI. All experiments were 
performed with 10-14 weeks old age-matched and gender-matched animals. 
Both male and female animals were used for every experiment to exclude 
influence of gender. 
 
Microbiota manipulation: Alteration of microbiota composition was 
conducted by cohousing or fecal transplantation. For cohousing both recipient 
and donor mice were cohoused at least 4 weeks prior starting experiment. For 
fecal transplantation donor mice were euthanized, intestinal content was 
collected in BBL thioglycollate media (BD Bioscience) and homogenized by 
vortexing. To remove course particle under anaerobic conditions the content 
was filtered through 70um sterile filter. After centrifugation (10min, 500g, 40C), 
the pellet containing fecal bacteria was resuspended in BHI medium (Sigma-
Alrich). After 2-hr of starving recipient mice were orally gavaged with a total 
200ul of fecal bacterial content. Again a 4 week time period was given for a 
successful establishment of fecal transplanted bacteria (unless mentioned 
otherwise). Every microbiota manipulation was further confirmed by 16S rRNA 
sequencing of fecal bacteria.  
 
DNA isolation and 16S rRNA microbial community analysis: Fresh stool 
samples of mice were collected and immediately stored at -20°C. DNA was 
extracted according to established protocols using a method combining 
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mechanical disruption (bead-beating) and phenol/chloroform-based 
purification 25. Briefly, sample was suspended in a solution containing 500µl of 
extraction buffer (200 mM Tris, 20mM EDTA, 200mM NaCl, pH 8.0), 200µl of 
20% SDS, 500µl of phenol:chloroform:isoamyl alcohol (24:24:1) and 100µl of 
0.1 mm zirconia/silica. Samples were homogenized twice with a bead beater 
(BioSpec) for 2 min. After precipitation of DNA, crude DNA extracts were 
resuspended in TE Buffer with 100µg/ml RNase and column purified to 
remove PCR inhibitors (BioBasic). Amplification of the V4 region (F515/R806) 
of the 16S rRNA gene was performed according to previously described 
protocols 26. Samples were sequenced on an Illuminia MiSeq platform 
(PE250). Filtering of sequences for low quality reads (q>=30) and barcode-
based binning was performed by using QIIME v1.8.0 (Caporaso et al., 2010). 
Reads were clustered into 97% ID OTUs using UCLUST reference OTU 
picking, followed by taxonomic classification using the RDP Classifier 
executed at 80% bootstrap confidence cut off 27,28. Sequences without 
matching reference dataset, were grouped as de novo using UCLUST. The 
OTU absolute abundance table and mapping file were used for statistical 
analyses and data visualization in the R statistical programming environment 
package phyloseq 29. To determine bacterial OTUs that explained differences 
between microbiota settings, linear discriminant analysis (LDA) effect size 
(LEfSe) method were used 30. OTUs with Kruskal-Wallis test <0.05 and LDA 
scores >3.5 were considered informative. 
 
Dextran sodium sulfate (DSS) induced colitis: To induce acute colitis, mice 
were provided 2% (w/v) DSS (molecular mass= 36-50 kDa, MP Biomedicals) 
in drinking water for 7 days followed by 7 days of access to regular drinking 
water. Daily clinical assessment of DSS-treated animals included body weight 
loss measurement, stool consistency, detection of blood in stool. 
Experimental samples were collected at day 0, 5, 7 of DSS treatment. 
 
Histology: At day 5 of DSS-treatment colon samples were collected, rolled up 
to “swiss roles”, fixed in 4% neutrally buffered formaldehyde and embedded in 
paraffin according to standard histological procedures. Sections of 3µm 
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thickness were stained with hematoxylin-eosin (HE) and evaluated by light 
microscopy blinded to the experimental groups. 
The histological scoring used to evaluate the severity of colitis in DSS treated 
mice microscopically, was adapted from the TJL-score, which was developed 
for scoring colitis in mice by The Jackson Laboratory 31. The alteration of the 
score has been previously described 32. The colon was divided into a proximal 
(oral), middle and distal (aboral) section, each of about the same size. The 
three sections were scored for the general criteria: severity (0-3), ulceration 
(0-3), oedema (0-3), goblet cell metaplasia (0-3), and area involved (0-3) 
where score 0 depicted no alteration to score 3 massive alteration in the given 
parameters. 
The scores were added up to a total of up to 15 per section and the scores of 
the three sections to a total of up to 45 per colon sample.  
 
Colonoscopy: Colonoscopy was performed using a high-resolution mouse 
video endoscopic system (‘Coloview’, Carl Storz, Tuttlingen, Germany). The 
severity of colitis was blindly scored using MEICS (Murine Endoscopic Index 
of Colitis Severity), which is based on five parameters: granularity of mucosal 
surface (0-3); vascular pattern (0-3); translucency of the colon mucosa (0-3); 
visible fibrin (0-3); and stool consistency (0-3) 33.  
 
Isolation of colonic lamina propria leukocytes (cLPL) and flow 
cytometry: To isolate cLPL, density gradient centrifugation using Percoll was 
done as previously described 34. In brief, colons were collected during steady 
state and at d5 of DSS treatment. Fecal content was removed, tissues were 
opened longitudinally, washed with PBS and then shaken in HBSS containing 
2 mM EDTA for 20 min at 37°C. Tissues were cut into small pieces and 
incubated with digestion solution (DMEM containing 1% fetal bovine serum 
(FBS), 0.25 mg/ml collagenase D, 0.5 U/ml dispase and 5 μg/ml DNase I) in 
a shaker for 20 min at 37°C. Digested tissues were filtered through 70uM cell 
strainer (Falcon) and DMEM + 5% FBS was added to inactivate enzymes. 
The last two steps were repeated until all tissue was digested. After 
centrifugation, cells were resuspended in 4 ml of 40% Percoll (GE Healthcare) 
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and overlaid on 4 ml of 80% Percoll. Percoll gradient separation was 
performed by centrifugation at 450 g for 25 min at 25°C. Cells in the 
interphase were collected and used as LPL. The collected cells were then 
suspended in staining buffer containing PBS, 1% FBS and 2 mM EDTA. The 
following antibodies were used: anti-CD45 (30-F11), anti-CD3 (17A2), anti-
B220 (RA3-6B2), anti-CD4 (RM4-5, GK1.5), anti-CD8a (53-6.7), anti-TCR-
gamma/delta (GL3), anti-CD44 (IM7), anti-CD62L (MEL-14), anti-MHC class II 
(M5/114.15.2), anti-CD11b (M1/70), anti-CD11c (N418), anti-Ly6G (IA8), anti-
Ly6C (HK1.4) (Biolegend). To distinguish live dead cells AlexaFluor-350 NHS 
Ester (Life Technologies) was used. Flow cytometry analysis was performed 
using a BD LSR (BD Biosciences) and data were analyzed with FlowJo 
software (TreeStar Inc.). 
 
In-vitro T cell activation of cLPL: For T cell activation freshly isolated cLPL 
(200,000/well) were cultured in 96-well round-bottom plates in complete 
culture medium containing soluble, plate-bound, anti-CD3 (1mg/ml) and 
soluble anti CD28 (5mg/ml) (Biolegend) for 3 days. Supernatant were 
collected after 3 days for cytokines and chemokines measurement.  
 
Collection of colonic tissue homogenate: Colonic tissue homogenate was 
collected from euthanized mice during steady state and d7 colitis. Colons 
were excised into proximal and distal colon. Each part was cut longitudinally 
and cleaned by washing with autoclaved 1x PBS. Parts of proximal or distal 
colon were weighed and homogenized mechanically using Mini-Beadbeater-
96 (Biospec) in NP-40 lysis buffer containing protease inhibitors (Complete 
Mini EDTA-free, Roche). Protein extracts were centrifuged (10,000 r.p.m. for 5 
min at 4°C) and the supernatants were collected as tissue homogenate 
samples and stored at -80°C.  
 
Cytokine detection- ELISA, multiplex and Legendplex: Concentration of 
IL-18 in the tissue homogenates was measured using the following 
commercial ELISA kits: IL-18 (MBL) according to manufacturer’s instruction. 
Different other cytokines and chemokines were measured by using the 
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ProcartaPlex Multiplex Immunoassay (eBioscience) and FACS based 
Legendplex kit (Biolegend) according to the manufacturer’s instructions.  
 
RNA isolation and quantitative PCR: Tissues were preserved in RNAlater 
solution (Ambion) and subsequently homogenized in Trizol reagent 
(Invitrogen). One microgram of total RNA was used to generate cDNA by the 
protocol for first strand cDNA synthesis using RevertAid RT (Thermo 
Scientific). RealTime-PCR was performed using gene-specific primer sets 
(Applied Biosystems) of Cd4 primer (F: 5’-TAGCAACTCTAAGGTCTCTAAC 
and R: 5’-GATAGCTGTGCTCTGAAAAC) and Kapa Sybr Fast qPCR kit 
(Kapa Biosystems) on a LightCycler 480 instrument (Roche). PCR conditions 
were 950C for 60 s, followed by 40 cycles of 950C for 3 s and 600C for 30 s. 
Data were analyzed using the the deltaCt method with hprt (F: 
CTGGTGAAAAGGACCTCTCG and R: 
TGAAGTACTCATTATAGTCAAGGGCA) serving as the reference 
housekeeping gene. 
RNA-Seq Analysis: Total RNA isolation from distal colonic tissue was 
performed as described at the RNA isolation section. RNA integrity was 
measured in a Bioanalyzer (Agilent Technologies, USA) and samples were 
selected according to RNA Integrity Number (RIN) > 9. Isolation of mRNA was 
performed with Dynabeads mRNA DIRECT Micro Kit (Ambion, USA) using 
1ug of total RNA. Furthermore, cDNA synthesis, fragmentation and 
sequencing library preparation were done using ScriptSeq v2 RNA-Seq Kit 
(PCR 15 cycles) (Illumina, USA). Sequencing was performed through Illumia 
Hi-seq 2000 platform in single end mode for 50bp.  
We obtained and average of 52,2Mio of reads per sample (n=16).  Reads 
were quality filtered using Trimmomatic with as follow parameters 
(LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:35 
HEADCROP:3). After quality control reads were aligned to the mouse 
reference genome (mm10) using STAR 
(https://www.ncbi.nlm.nih.gov/pubmed/23104886). Reads count to each gene 
Chapter 2 
 
 
 49 
was evaluated using HTseq(https://www.ncbi.nlm.nih.gov/pubmed/25260700). 
Normalization and differential expression were quantified using the DEseq2 
package 
(https://www.ncbi.nlm.nih.gov/pubmed/?term=Moderated+estimation+of+fold+
change+and+dispersion+for+RNA-seq+data+with+DESeq2). Differential 
expressed gene networks were analyzed with Consensus Path DB-mouse 
webserver 
(https://www.ncbi.nlm.nih.gov/pubmed/?term=The+ConsensusPathDB+intera
ction+database%3A+2013+update). Data was visualized using ggplot2 R 
library.  
Antibody-mediated depletion: Anti-CD4 (clone GK1.5) and anti-CD8a (2.43) 
neutralizing antibodies and an isotype control mAb (clone LTF-2) (Bio X Cell) 
were used. For each antibody, 200ug injections were given intraperitoneally 
(i.p.) at day -1, day 3 and day 7 of DSS treatment. Isolating cLPL and splenic 
lymphocytes followed by flow cytometry assessed depletion efficiency.  
CD45Rbhi colitis: CD4+Foxp3-CD45RB(high) cells were transferred 
adoptively into Rag2-/- mice according to the protocol described in 35. Briefly, 
splenic lymphocytes were isolated from IL-17AGFP IFN-γKatushka FoxP3RFP triple 
reporter mice. CD4 enrichment was performed according to the manufacturer 
instruction using CD4 (L3T4) Microbeads (Miltenyi Biotec). CD4 enriched cells 
were then stained with CD45RB, CD4. Cells were sorted in BD FACSAria II 
cell Sorter by gating CD45RB(high), CD4+Foxp3- cells. Anbodies used for 
staining were anti-CD45RB (C363-16A), anti-CD4 (GK1.5). A total of 500,000 
cells were injected i.p./mouse. Disease development was monitored by 
weighing animals 3 times a week and performing colonoscopy. 
 
Statistical analyses: Statistical analysis was performed using GraphPad 
Prism program (GraphPad Software). Data are expressed as mean ± SEM. 
Differences were analyzed by Student’s t test and ANOVA. P values indicated 
represent a non-parametric Mann-Whitney U test or Kruskal-Wallis test 
comparison between groups. P values ≤ 0.05 were considered as significant: 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
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2.4 Results 
 
2.4.1 DSS colitis severity is strongly influenced by microbiota 
composition in SPF mice 
 
 
Figure 2.1 Isogenic mice from different breeding facilities demonstrate 
variable susceptibility to DSS induced colitis. 
(A-D) DSS colitis was induced in SPF WT (SPF-1 – SPF-6) and dysbiotic Nlrp6-/- (DysM) mice 
by administering 2% DSS (w/v) for 7 days. Body weight and survival of mice were examined 
on daily basis for 10 days (A). Body weight on d8 DSS (B), during entire experiment body 
weight (C) and survival (D) of mice described in Figure 1A. DSS severity is depicted as “o” 
being mild and “+” being severe. Data represent n=6-18 mice/group as mean ± SEM from at 
least two independent experiments. P values indicated represent a unpaired Student’s t test. 
*p < 0,05; **p < 0,01; ***p< 0,001; ****p< 0,0001. 
 
Distinct differences in microbiota composition between isogenic mice from 
commercial vendors, e.g. the presence of segmented filamentous bacteria 
(SFB), have been found to influence the outcome of disease models in mice 
36. To investigate whether C57BL/6N mice differ in their susceptibility to 
intestinal inflammation after chemical-induced damage to the intestinal barrier, 
we induced DSS colitis in SPF mouse lines obtained from vendors or bred in-
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house (Figure 2.1A). After mice were exposed to DSS (2 % w/v) for 7 days 
severity of disease was compared within lines of SPF mice and to previously 
described dysbiotic Nlrp6-/- mice (Figure 2.1B, 2.1C and 2.1D)20. SPF-1, SPF-
5, and SPF-6 mice were characterized by a mild colitis with moderate weight 
loss and no mortality, but SPF-2, SPF-3, and SPF-4 mice as well as dysbiotic 
Nlrp6-/- mice developed a similar severe colitis with profound loss of body 
mass and mortality (Figure 2.1B, 2.1C and 2.1D).  
Next, we investigated fecal microbiota composition before induction of DSS 
colitis in SPF and DysM mice using 16S rRNA sequencing. Analysis of β 
diversity using PCoA showed that mice with mild colitis severity (SPF-1, SPF-
5 and SPF-6) clustered separately from mice featuring a high severity of 
colitis (SPF-2, SPF-3, SPF-4, and DysM). We noted a high similarity between 
SPF-2, SPF-3 (both from different barriers of the same vendor), and SPF-4 
mice as well as between SPF-5 and SPF-6 mice (both from different barriers 
of the same vendor), respectively, whereas SPF-1 and DysM mice clustered 
distinctly (Figure 2.2A). More detailed analysis revealed that species richness 
(Chao index) was lower in SPF-1 mice, but that complexity of community 
structure (Shannon index) was not significantly different between mouse lines 
(Figure 2.2B). Global changes in the composition of microbiota have been 
associated with IBD 6, such as decrease in the level of resident Firmicutes 
and/or Bacteroides and an overabundance of Proteobacteria 37. We observed 
a significant expansion of Bacteroides over Firmicutes in colitogenic SPF-2, 
SPF-3, SPF-4 and DysM mice compared to SPF-1, SPF-5 and SPF-6 mice 
(Figure 2.2C). Overgrowth in Proteobacteria was highest in DysM mice, 
followed by SPF-2, SPF-3, SPF-4 and SPF-5 mice and was mostly absent in 
SPF-1 and SPF-6 mice (Figure 2.2C). A detailed microbiota composition of 
different groups used in this study is given in Figure 2.2D. 
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Figure 2.2 Comparison of microbiota composition of different isogenic mouse 
lines. 
(A-D) 16S rRNA sequencing of fecal microbiota of mice described in Figure 1A before DSS 
colitis induction. Analysis of β-diversity (PCoA) (A), α-diversity (Chao1 and Shannon) (B) ratio 
of relative abundances between Firmicutes to Bacteroides and Firmicutes to Proteobacteria 
(C) and relative abundances of different microbial families (D). Data represent n=6-33 
mice/group as mean ± SEM from at least two independent experiments. P values indicated 
represent a unpaired Student’s t test *p < 0.05; **p < 0.01; ***p< 0.001; ****p< 0.0001. 
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Inbred mouse lines differ vastly in their susceptibility to DSS colitis. To 
exclude the effect of genetic drift in inbred mice from different sources, we 
performed cohousing experiments with microbiota donor and germfree 
recipient mice. We focused on SPF-1 (low susceptibility, higher Firmicutes), 
SPF-2 (high susceptibility, higher Bacteroides) and DysM mice (high 
susceptibility, higher Bacteroides and higher Proteobacteria) representing the 
different colitis outcomes and microbiota compositions. Transfer of the donor 
microbiota into GF recipient (exGF) mice was confirmed by 16S rRNA 
sequencing (Figure 2.3A). Upon induction of DSS colitis exGF mice 
phenocopied the respective donor mice supporting that the differences in 
colitis severity were dependent on the microbiota (Figure 2.3A). Similar 
microbiota-driven phenotypes were confirmed for SPF-5 and SPF-6 
communities (data not shown). This data demonstrate that distinct types of 
microbial communities that are stably maintained in WT mice are able to alter 
the host’s susceptibility to DSS colitis. 
 
 
 
 
Figure 2.3 Enhanced colitis susceptibility is dependent only on microbiota 
compositioin. 
(A) Germ-free C57BL/6N mice were cohoused with donor SPF WT (SPF-1, SPF-2) and Nlrp6-
/- (DysM) mice followed by induction of DSS colitis. Analysis of β-diversity (PCoA) before and 
disease severity (body weight and survival) upon induction of DSS colitis. Data represent 
n=6-15 mice/group as mean ± SEM from at least two independent experiments. P values 
indicated represent a unpaired Student’s t test *p < 0.05; **p < 0.01; ***p< 0.001; ****p< 
0.0001. 
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2.4.2 Transfer of colitogenic microbial communities into an 
immunocompetent host induces distinct patterns of host gene 
expression and alters colitis susceptibility 
  
Next, we investigated whether the degree of colitis severity was also 
transferable between SPF mice with variable DSS colitis susceptibility similar 
to what has been observed for Nlrp6 inflammasome deficient mice (DysM)20. 
Therefore, we performed cohousing experiments of mice featuring a mild 
colitis (SPF-1) with mice having a high colitis severity (SPF-2 and DysM). 
Cohousing for 4 weeks resulted in a reshaping of the microbiota in SPF-1 
mice cohoused with SPF-2 mice (SPF-1 + SPF-2) and DysM mice (SPF-1 + 
DysM) compared to SPF-1 control mice, respectively (Figure 2.4A). Moreover, 
cohousing also transferred colitis susceptibility as indicated by enhanced 
weight loss and mortality in SPF-1 + SPF-2 and SPF-1 + DysM mice (Figure 
2.4B). Since SPF-1 + SPF-2 and SPF-1 + DysM behaved like SPF-2 and 
DysM mice, we therefore referred to them in the following as cSPF-2 and 
cDysM (cohoused SPF-2/DysM), respectively. A similar transfer of colitis 
severity was also achieved by cohousing of SPF-2 with SPF-6 mice (Figure 
2.4F) and after fecal transplantation (FT) from SPF-2 and DysM mice into 
SPF-1 mice (Data not shown). Increased colitis severity in cSPF-2 and cDysM 
mice was also illustrated by enhanced colon shortening and corroborated by 
histological characterization of tissue damage as well as endoscopy (Figure 
2.4C, 2.4D, and 2.4E). This data demonstrates that distinct types of microbial 
communities are able to alter the host’s susceptibility to DSS colitis even in 
already colonized immunocompetent recipients.  
Induction of DSS colitis has been shown to alter the composition of the 
intestinal microbiota 38. To identify whether a shared group of commensals 
alters their abundance during DSS colitis in SPF-1 mice as well as in cSPF-2 
and cDysM mice, we compared their fecal microbial communities before and 
after induction of DSS colitis (d5). Strikingly, β-diversity analysis (PCoA), as 
well as analysis of relative abundances of different bacterial families revealed 
minor differences between the two time points for each community, 
respectively (Figure 2.5A and 2.5C). 
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Figure 2.4 Transfer of colitogenic community results in enhanced colitis 
severity in mice harboring non-colitogenic community. 
(A-E) SPF-1 WT mice were cohoused with either SPF-2 WT or DysM Nlrp6-/- (SPF-1 + DysM) 
mice resulting in SPF-1 + SPF-2 and SPF-1 + DysM mice, respectively. Analysis of β-
diversity (PCoA) of donor and recipient mice before induction of DSS colitis (A).  
(B-E) Acute DSS colitis was induced and body weight and survival of microbiota recipient 
mice was monitored for 10 days (B). Representative pictures and colitis severity score by 
colonoscopy performed on day 6 after colitis induction (D). Colon length was measured 5 
days after induction of DSS colitis. Representative image of excised colons (C). Histological 
analysis of distal colon was performed 5 days after induction of DSS colitis (E). 
Representative pictures of H&E-stained colon sections. Bar represents approx. 50µm.  
(F) SPF-6 WT mice were cohoused with SPF-2 WT resulting in SPF-6 (coh SPF-2) and SPF-
2 (coh SPF-6) mice. Analysis of β-diversity (PCoA) of non-cohoused SPF-6 and cohoused 
SPF-6 (coh SPF-2) and SPF-2 (coh SPF-6) mice before induction of DSS colitis. Acute DSS 
colitis was induced and body weight of mice was monitored for 10 days. Data represent n=4-
16 mice/group as mean ± SEM from at least two independent experiments. P values 
indicated represent a unpaired Student’s t test (B) and nonparametric Kruskal-Wallis test 
(C,D,E) *p < 0.05; **p < 0.01; ***p< 0.001; ****p< 0.0001. 
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Figure 2.5 Alteration in microbiota composition before and after colitis 
induction. 
(A-C) 16S rRNA sequencing of fecal microbiota from WT SPF-1, cSPF-2 and cDysM at d0 
and d5 of DSS colitis. Analysis of β-diversity (PCoA)(A). Analysis of differentially abundant 
microbial families in cDysM and cSPF-2 mice at d0 and d5 DSS by LEfSe (Kruskal-Wallis test 
p<0.05, LDA 4.0)(B). Relative abundances of different microbial families are displayed (C). 
Data represent n=5-11 mice/group as mean ± SEM from at least two independent 
experiments. 
 
Minor alterations included an increase in Verrucomicrobiaceae in cSPF-2 and 
an increase in abundance of some Bacteroidaceae in cDysM (Figure 2.5B 
and 2.5C), but no unified changes were observed between the cSPF-2 and 
cDysM community despite a similar induction of colitis at this time point. Since 
our data did not show unified alterations in fecal communities after DSS 
induction, we hypothesized that colitogenic communities already modulate 
host immunity before disease induction, which in turn results in enhancement 
of colitis severity. 
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Figure 2.6  Alteration of host responses by colitogenic microbiota. 
(A-C) RNAseq analysis from total colonic tissue of WT mice colonized with SPF-1, cSPF-2 or 
cDysM. Heatmap shows quantification of RNA reads (A). DEseq analysis compares 
significant up/down-regulation of genes (fold change > 2) in different microbiota conditions 
(B). Pathway analysis based on GO terms of genes significantly upregulated (2-fold) in 
cDysM mice compared to SPF-1 (H). Data represent n=4 mice/group. 
 
Hence, global gene expression in colonic tissues of mice harboring either 
SPF-1, cSPF-2 or cDysM was compared using RNA-seq. Interestingly, SPF-1 
and cSPF-2 mice clustered together and separate from cDysM mice (data not 
shown) with a distinct gene expression signature (Figure 2.6A and 2.6B). 
Specifically, pathway enrichment analysis showed that many upregulated 
genes in cDysM were involved in T cell and B cell signaling, as well as 
cytokine and chemokine signaling (Figure 2.6C). In contrast, despite the fact 
that a similar colitis severity outcome as observed in cDysM mice, SPF-2 
colonization of SPF-1 mice did not result in significant alterations in the host 
transcriptome (Figure 2.6A and 2.6B). These data together suggest that 
alteration of the SPF-1 community by colonizing them with the colitogenic 
SPF-2 or DysM triggers a very different response at the host transcriptional 
level and that the presence of different microbial families at baseline are 
enough to enhance such colitogenic microbiota induced pathologies in an 
immunocompetent host. .  
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2.4.3 DysM but not SPF-2 microbiota depends on adaptive immune cells 
to develop colitis 
 
 
Figure 2.7 Immunomodulation prior DSS induction is required for DysM, but 
not SPF-2 induced colitis. 
(A-G) SPF-1 mice were mock-transferred or received a fecal transplant from Nlrp6-/- DysM or 
WT SPF-2 donor mice 2d or 28d prior to colitis induction. 
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Since the transfer of the colitogenic SPF-2 community, unlike the DysM 
community, did not trigger large changes in the host transcriptome in the 
intestine, we hypothesized that the mere presence of the SPF-2 community 
may be sufficient to trigger more severe colitis upon damage to the intestinal 
barrier. Therefore, we assessed disease severity in SPF-1 mice that received 
FT of the SPF-2 or DysM community 2 days or 28 days prior to disease 
induction, respectively. Despite minor but detectable differences in 
communities of mice receiving FT for 2 or 28 days (Figure 2.7A, 2.7C and 
2.7G), already a brief colonization with the SPF-2 microbiota was sufficient to 
transfer exacerbated disease severity that was comparable to the result 
following extended colonization (Figure 2.7B). In contrast, brief colonization 
with the DysM microbiota did not transfer heightened disease susceptibility 
(Figure 2.7D). This inability of the DysM microbiota to transfer colitis severity 
potentially results from incomplete microbiota transfer, a requirement for 
extended immunomodulation or priming of adaptive immune responses. 
Comparison of the communities in mice receiving the DysM FT for 2 or 28 
days by LEfSe analysis revealed very minute differences (Figure 2.7E), 
including a higher abundance of SFB as well as Odoribacteriaceae 28 days 
after the transfer. Notably, despite successful transfer of colitis severity, 
communities differed stronger in the case of SPF-2 FT (Figure 2.7F). 
Interestingly, similar to the DysM FT, SFB and Odoribacteriaceae displayed 
higher abundances 28 days after SPF-2 transfer. This suggests that these 
bacteria may not be involved in modulating DSS colitis severity.  
 
Figure 2.7 (cont.) (A, C) PCoA plot of fecal microbiota composition at steady state of WT 
SPF-1 mice receiving SPF-2 (A) or DysM (C) microbiota for different time periods. (B, D) 
Body weight and survival of WT SPF-1 mice receiving SPF-2 (B) or DysM (D) microbiota for 
different time periods during DSS colitis. (E-F) Analysis of differentially abundant microbial 
families in mice with short (2d) and prolonged (28d) exposure to DysM (E) and SPF-2 (F) 
were analyzed by LEfSe (Kruskal-Wallis test p<0.05, LDA 2.0) before induction of DSS colitis. 
(G) Relative abundance of different bacterial families in fecal microbiota in mice with short 
(2d) and prolonged (28d) exposure to DysM and SPF-2 before DSS induction. 
Data represent n=3-15 mice/group as mean ± SEM from at least two independent 
experiments. P values indicated represent a unpaired Student’s t test *p < 0,05; **p < 0,01; 
***p< 0,001; ****p< 0,0001. 
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Figure 2.8 Adaptive immune system is important for DysM mediated colitis. 
(A-F) SPF-1 WT and SPF-1 Rag2-/- recipients were cohoused with donor DysM or SPF-2 and 
body weight was monitored upon colitis induction (B, D) respectively. Analysis of β-diversity 
(PCoA) of DysM recipients (A) and SPF-2 recipients (C) is shown along with multivariate 
analysis of variance (ADONIS test) of variables ‘microbiota composition’, ‘genotype’ and 
‘cage’. 
(E-F) SPF-1 and cDysM WT and Rag2-/- were sacrificed on d5 of DSS colitis and colons were 
excised. Colon length was measured (E) and survival of mice with different microbiota are 
given (F). Data represent n=5-15 mice/group as mean ± SEM from at least two independent 
experiments. P values indicated represent a unpaired Student’s t test *p < 0,05; **p < 0,01; 
***p< 0,001; ****p< 0,0001. 
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Next, to test whether DysM requires priming of adaptive immunity, we 
compared the severity of DSS colitis between Rag2-/- mice harboring either 
the SPF-1, cSPF-2 or cDysM communities. Therefore, SPF-1 Rag2-/- mice 
were cohoused with either DysM or SPF-2 donor mice. Strikingly, unlike in 
WT mice, cDysM could not enhance colitis severity in Rag2-/- mice as 
indicated by similar weight loss (Figure 2.8B) and colon length (Figure 2.8E) 
between Rag2-/- mice with SPF-1 and cDysM. In contrast, cSPF-2 induced 
severe colitis also in Rag2-/- mice as indicated by increased weight loss and 
mortality (Figure 2.8D and 2.8F). Importantly, we confirmed comparable 
transfer of the donor communities into WT and Rag2-/- mice (Figure 2.8A and 
2.8C). We used permutational multivariate analysis of variance (ADONIS) 39, 
considering the variables “genotype”, “microbiota”, and “cage” to evaluate 
their relative contribution to variability within the groups (Figure 2.8A and 
2.8C). This analysis revealed that genotype contributed only 3% of variability, 
while microbiota contributed around 60%.  Together these data demonstrate 
that extended immunomodulation and priming of adaptive immunity by DysM 
but not SPF-2 is required to exacerbate colitis severity. 
 
2.4.4 Colitis development is characterized by the presence of distinct 
immune signatures in DysM and in SPF-2 mice 
 
Despite a similar disease severity in DysM and SPF-2 mice upon DSS colitis 
induction, our initial results corroborated the hypothesis that distinct 
colitogenic communities contribute to disease development via different 
pathways. To further compare intestinal inflammation induced in cDysM 
compared to cSPF-2 mice, presence of cytokines and chemokines were 
measured in tissue homogenates at day 7 of DSS colitis. 
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Figure 2.9 Colitis driven by DysM and SPF-2 are characterized by distinct 
cytokine profile. 
(A-B) DSS colitis was induced in WT mice harboring SPF-1, cDysM or cSPF-2 communities. 
Colon samples were collected at day 7 of DSS and divided into two parts as proximal (PC) 
and distal (DC) colon. Cytokines (A) and chemokines (B) were measured using 
Multiplex/LEGENDplex kit from colonic tissue homogenates. Data represent n=7-17 
mice/group as mean ± SEM from at least two independent experiments. P values indicated 
represent a nonparametric Kruskal-Wallis test *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 
0,0001. 
 
Levels of the pro-inflammatory cytokines IL-6 and IL-17A were significantly 
higher in the distal colon of both cDysM and cSPF-2 mice compared to SPF-1 
mice (Figure 2.9A). Compared to SPF-1 and cDysM, colitis induced in cSPF-2 
mice was distinctively characterized by higher levels of IFN-γ, IL-22 and TNF-
α as well as lower levels of IL-18 mainly in the distal colon (Figure 2.9A). No 
changes were observed in IL-2, IL-4, IL-5, IL-10, IL-13 between the three 
microbiota communities (data not shown). In line with our previous 
observations 20, higher levels of the chemokine CCL5 were detected in the 
proximal colon of cDysM mice compared to SPF-1 and cSPF-2 mice (Figure 
2.9B). In contrast, several other chemokines including LIX and KC, which 
recruit and activate neutrophils, along with MIP-1a and MIP-1b were 
significantly increased during colitis induced by cSPF-2 (Figure 2.9B).  
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Figure 2.10 Increased neutrophil infiltratioin in SPF-2 mice during DSS colitis. 
(A-D) Colonic lamina propria leukocytes (cLPL) were isolated from WT mice harboring SPF-1, 
cDysM or cSPF-2 microbiota during steady state (d0) and on d5 after DSS induction and 
analyzed by FACS. Total number of CD45+ cells in cLPL (A). Analysis of neutrophil infiltration 
upon DSS induction. Representative FACS plots showing frequencies of neutrophils (B). 
Frequencies (C) and total numbers (D) of neutrophils at d0 and d5 DSS. Data represent n=6-
14 mice/group as mean ± SEM from at least two independent experiments. P values 
indicated represent a nonparametric Kruskal-Wallis test *p < 0,05; **p < 0,01; ***p< 0,001; 
****p< 0,0001. 
 
In parallel, we analyzed lamina propria leukocytes (LPLs) from colonic tissue 
by flow cytometry to identify whether distinct immune cell subsets are 
associated with disease induced by SPF-1, cDysM and cSPF-2 communities. 
Indeed, 2-fold increased numbers of CD45+ cells were observed in cDysM 
WT mice compared to SPF-1 and cSPF-2 WT mice both before and 5 days 
after induction of DSS colitis (Figure 2.10A). In line with the enhanced levels 
of neutrophil-attracting chemokines, colitis in cSPF-2 mice was associated 
with a specific increase in the relative abundance and total number of 
neutrophils (Figure 2.10B, 2.10C and 2.10D).  
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Figure 2.11 Colitis driven by DysM is characterized by distinct infiltration of 
adaptive immune cells. 
(A-D) Colonic lamina propria leukocytes (cLPL) were isolated from WT mice harboring SPF-1, 
cDysM or cSPF-2 communities during steady state (d0) and d5 of DSS colitis and analyzed 
by FACS. Gating strategy of FACS data to analyze different adaptive immune cells (A). 
Representative FACS plots showing CD4 and CD8 frequencies gated on CD3+ cells and 
frequencies of naïve and activated CD4+ T cells during steady state (B). Frequencies of 
different immune cells at d0 and d5 of DSS (C). Total numbers of indicated immune cell 
subsets at d0 and d5 of DSS (D). Data represent n=5-17 mice/group as mean ± SEM from at 
least two independent experiments. P values indicated represent a nonparametric Kruskal-
Wallis test *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 0,0001. 
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Despite similar frequencies of immune cell subsets of the adaptive immune 
system (Figure 2.11A, 2.11B and 2.11C), significant increases in the numbers 
of B220+ B cells and CD3+ T cells were observed before and after induction 
of DSS colitis in cDysM mice (Figure 2.11D). Increases in the numbers of 
CD4+ and CD8+ T cells but not γδ T cells contributed to this difference (Figure 
2.11D). During, but not before DSS colitis, a higher frequency of CD4+ T cells 
in the colon of cDysM and cSPF-2 mice displayed an activated phenotype 
(Figure 2.11C). Notably, absolute numbers of activated CD4+ T cells were 
only increased in cDysM mice, both before and after induction of DSS colitis 
(Figure 2.11D). These analyses show that two colitogenic communities trigger 
distinct inflammatory immune pathways, i.e. enhanced neutrophil recruitment 
and pathogenic adaptive immune cell responses during DSS colitis.   
 
2.4.5 αβ T cells trigger DysM but not SPF-2 mediated colitis 
development 
 
In order to investigate which type of pathogenic adaptive immune responses 
contribute to disease exacerbation after colonization with the DysM 
community, we decided to compare severity of DSS colitis in WT as well as B 
or T cell deficient mice in SPF-1 and cDysM conditions. To assure 
comparable microbiota composition in WT and gene-deficient mice at 
baseline, all gene-deficient mouse lines were initially rederived into SPF-1 
conditions using embryo transfer. Indeed, analysis of β diversity in the fecal 
microbiota demonstrated that SPF-1 communities in WT and gene-deficient 
mice were indistinguishable (Galvez E et al., manuscript submitted). To then 
generate experimental cohorts of WT and gene-deficient mice, the DysM 
microbiota was transferred into SPF-1 recipients using FT or cohousing and 
composition of the fecal microbiota was recorded before induction of disease. 
To investigate an involvement of T and B cells, we studied SPF-1 and cDysM 
Tcrbd-/- and muMT-/- mice, respectively.  
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Figure 2.12 T cells are required for DysM mediated colitis. 
(A-H) SPF-1 WT, Tcrbd-/- and muMT-/- mice were cohoused with DysM donor mice. Fecal 
microbiota composition was analyzed by 16S rRNA sequencing before induction of DSS 
colitis. Analysis of β-diversity (PCoA) of SPF-1 and cDysM WT and Tcrbd-/- mice (A) or 
muMT-/- mice (E) is shown along with multivariate analysis of variance (ADONIS test) of 
variables ‘microbiota composition’, ‘genotype’ and ‘cage’. After DSS colitis induction body 
weight loss was measured in WT and Tcrbd-/- mice (B) or muMT-/- mice (F). Representative 
pictures and colitis severity score by colonoscopy performed on day 6 after colitis induction in 
SPF-1 and cDysM WT and Tcrbd-/- mice (D). 5 days after colitis induction colon shortening 
was measured (G) and histological analysis of distal colon was performed. Representative 
pictures of H&E-stained colon sections and scores in WT and Tcrbd-/- mice (C) or muMT-/- 
mice (H). Bar represents approx. 50µm. Data represent n=5-26 mice/group as mean ± SEM 
from at least two independent experiments. P values indicated represent a unpaired Student’s 
t test *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 0,0001. 
 
Chapter 2 
 
 
 67 
Comparison of microbiota composition and multi-variate analysis before start 
of DSS colitis revealed that mice clustered according to SPF-1 and cDysM 
communities with genotype contributing only little (i.e. 3 %) to differences in 
microbiome composition (Figure 2.12A and 2.12E). Despite similar transfer of 
DysM into WT and Tcrbd-/- mice, strikingly, no differences in severity of DSS 
colitis was observed between SPF-1 and cDysM Tcrbd-/- mice as indicated by 
similar weight loss, unlike in WT mice that showed microbiota-modulated 
disease severity (Figure 2.12B). An involvement of T cells in transferring 
exacerbated disease severity was further corroborated by analyzing intestinal 
inflammation using histology (Figure 2.12C) and endoscopy (Figure 2.12D) as 
well as quantifying colon shortening (Figure 2.12G) of WT and Tcrbd-/- mice. 
In contrast to WT mice, deficiency in T cells resulted in no detectable 
differences in these parameters between SPF-1 and cDysM Tcrbd-/- mice. 
Transfer of the DysM community in SPF-1 muMT-/- mice resulted in an 
exacerbation of DSS colitis severity as indicated by significantly enhanced 
weight loss (Figure 2.12F), colon shortening (Figure 2.12G) and heightened 
intestinal inflammation (Figure 2.12H) compared to SPF-1 muMT-/- mice 
suggesting a limited involvement of B cells in colitis exacerbation.  
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Figure 2.13 T or B cells are not required for SPF-2 mediated colitis. 
(A-C) SPF-1 WT, Tcrbd-/- and muMT-/- were cohoused with SPF-2 donor mice. Fecal 
microbiota composition was analyzed by 16S rRNA sequencing before induction of DSS 
colitis. Analysis of β-diversity (PCoA) of SPF-1 and cSPF-2 WT and Tcrbd-/- mice (A) or 
muMT-/- mice (B) is shown along with multivariate analysis of variance (ADONIS test) of 
variables ‘microbiota composition’, ‘genotype’ and ‘cage’. 
(C) DSS colitis was induced in SPF-1 and cSPF-2 WT, Tcrbd-/- and muMT-/- mice. Body 
weight was monitored over 10 days after DSS induction. Data represent n=5-15 mice/group 
as mean ± SEM from at least two independent experiments. P values indicated represent a 
unpaired Student’s t test *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 0,0001. 
 
To investigate, whether T cells are also required for disease exacerbation by 
the colitogenic SPF-2 microbiota, we introduced the SPF-2 community into 
SPF-1 WT, Tcrbd-/- and muMT-/- mice. After confirming that the fecal 
microbiota of mice clustered according to their microbial communities and not 
by genotype (Figure 2.13A, 2.13B), we induced DSS colitis. As expected from 
the results with Rag2-deficient mice, deficiency in B or T cells alone did not 
affect the transfer of heightened disease severity by cSPF-2 (Figure 2.13C).  
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Figure 2.14 αβ T cells are required for DysM-mediated colitis. 
(A-D) SPF-1 WT and Tcrd-/- mice were cohoused with DysM donor mice. Analysis of b-
diversity (PCoA) of fecal microbiota from SPF-1 and cDysM WT and Tcrd-/- mice (A) is shown 
along with multivariate analysis of variance (ADONIS test) of variables ‘microbiota 
composition’, ‘genotype’ and ‘cage’. After DSS induction body weight was measured daily (B). 
5 days after colitis induction colon lengths of WT and Tcrd-/- mice were measured (I) and 
histology analysis of distal colon was performed. Representative pictures of H&E-stained 
colon sections and histology scores (D). Bar represents approx. 50µm. Data represent n=4-
19 mice/group as mean ± SEM from at least two independent experiments. P values 
indicated represent a unpaired Student’s t test *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 
0,0001. 
 
γδ T cells have been implicated in colonic tissue repair 40, hence, we next 
characterized DSS colitis severity in SPF-1 and cDysM Tcrd-/- mice. Notably, 
characterization of fecal microbiota demonstrated that mice clustered 
according to SPF-1 and cDysM microbiota (Figure 2.14A). Similar to what we 
observed in WT mice, transfer of DysM microbiota induced in Tcrd-/- mice 
enhanced weight loss (Figure 2.14B), colon shortening (Figure 2.14C) and 
heightened intestinal inflammation (Figure 2.14D). From these results we 
concluded that T cells are essential for DysM but not SPF-2 induced 
exacerbation of disease. Specifically, our data suggests that modulation of αβ 
T cells by members of the DysM community is important. Finally, we exclude 
a major contribution of B cells to DysM-mediated colitis.  
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2.4.6 Pathogenic CD4+ T cells are crucial to induce DysM-mediated 
colitis 
 
 
Figure 2.15 CD4+ T cells are crucial to develop DysM, but not SPF-2 
mediated colitis. 
(A-G) SPF-1 WT, CD8-/- and CD4-/- mice were cohoused with DysM donor mice and 16S 
rRNA sequencing of fecal microbiota was performed before induction of DSS colitis.  
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CD4+ but also CD8+ T cells contribute to different aspects of intestinal 
homeostasis and inflammation 5. To specifically probe an involvement of 
these T cell subsets, we decided to compare DSS colitis severity in SPF-1 
and cDysM CD4-/- and CD8-/- mice. Fecal microbiota of mice clustered again 
according to SPF-1 and cDysM but not to genotype (Figure 2.15A and 2.15C). 
After DSS induction, CD8-/- but not CD4-/- showed enhanced weight loss and 
colitis severity after DysM transfer comparable to WT mice (Figure 2.15B, 
2.15D and 2.15E). Furthermore, analysis of intestinal inflammation using 
histology (Figure 2.15G) and quantification of colon shortening (Figure 2.15F) 
in SPF-1 and cDysM WT and CD4-/- mice corroborated that CD4+ but not 
CD8+ T cells are required for DysM-induced exacerbation of disease. To 
evaluate whether CD4+ T cells contribute to enhanced colitis severity by the 
colitogenic SPF-2 microbiota, we introduced the SPF-2 community into SPF-1 
WT and CD4-/- mice. Analysis of fecal microbiota of mice confirmed clustering 
according to microbiota and not by genotype (Figure 2.15H). Deficiency in 
CD4+ T cells did not affect the transfer of heightened disease severity (Figure 
2.15I), further supporting that SPF-2 drives colitis severity irrespective of T 
cells.  
 
Figure 2.15 (cont.) Analysis of β-diversity (PCoA) of SPF-1 and cDysM WT and CD8-/- mice 
(A) or CD4-/- mice (C) is shown along with multivariate analysis of variance (ADONIS test) of 
variables ‘microbiota composition’, ‘genotype’ and ‘cage’. After DSS colitis induction body 
weight loss was measured in WT and CD8-/- mice (B) or CD4-/- mice (d). Representative 
pictures and colitis severity score by colonoscopy performed on day 6 after colitis induction 
(E). 5 days after colitis induction colon shortening was measured (F) and histological analysis 
of distal colon was performed in WT and CD4-/- mice. Representative pictures of H&E-stained 
colon sections and histology scores (G). Bar represents approx. 50µm.  
SPF-1 WT and CD4-/- mice were cohoused with SPF-2 donor mice and 16S rRNA 
sequencing of fecal microbiota was performed before induction of DSS colitis. Analysis of β-
diversity (PCoA) is shown (H). Body weight was monitored (I). Data represent n=5-20 
mice/group as mean ± SEM from at least two independent experiments. P values indicated 
represent a unpaired Student’s t test *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 0,0001. 
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Figure 2.16 Distinct pathogenic CD4+ T cells are crucial for DysM to enhance 
colitis severity. 
SPF-1 and cDysM WT mice were injected with isotype control, anti-CD8 or anti- CD4 
antibodies at d-1, d3 and d7 of DSS colitis and. body weight was compared (A). 
Representative pictures, frequencies (B) and total numbers (C) of CD4+ T cells producing 
IFN-γ and/or IL-17A from isolated cLPL from IL-17AGFP IFN-γKatushka FoxP3RFP triple reporter 
mice with different microbiota. 
(D) cLPL were isolated from SPF-1, cDysM and cSPF-2 mice during steady state and on d5 
after DSS colitis induction and restimulated with α-CD3/CD28 for 3 days. Cytokine levels 
were measured from supernatant. Data represent n=5-20 mice/group as mean ± SEM from at 
least two independent experiments. P values indicated represent a unpaired Student’s t test 
(A) and nonparametric Kruskal-Wallis test (B-D) *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 
0,0001. 
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To investigate whether pathogenic CD4+ T cells are required during DysM-
enhanced DSS colitis, we treated SPF-1 and cDysM WT mice during DSS 
colitis with isotype control antibody or depleting antibodies against CD4 or 
CD8, respectively. Depletion of CD4 expressing cells but not CD8 expressing 
cells resulted in a failure of the DysM community to exacerbate DSS colitis 
(Figure 2.16A), highlighting that CD4+ T cells are required during the 
development of DysM-enhanced colitis. Consequently, we extended our 
immunophenotyping and analyzed the production of proinflammatory 
cytokines in CD4+ T cells before and during DSS colitis.  We initially focused 
on IFN-γ and IL-17 and hence, isolated cLPL from SPF-1, cSPF-2 and cDysM 
IL-17AGFP IFN-γKatushka FoxP3RFP triple reporter mice allowing the in situ 
monitoring of cytokine production 41. Transfer of the DysM but not SPF-2 
community resulted in enhanced numbers of IL-17A and IFN-γ single and IL-
17A/IFN-γ double cytokine-producing CD4+ T cells already before induction of 
DSS colitis (Figure 2.16B and 2.16C). After induction of DSS colitis, enhanced 
numbers of cytokine producing CD4+ T cells were observed in mice with both 
colitogenic communities (Figure 2.16B and 2.16C). In addition to monitoring 
cytokine production in situ, we isolated cLPL from SPF-1, cSPF-2 and cDysM 
mice before and after induction of DSS colitis and stimulated them with αCD3 
and αCD28 to quantify cytokine production from T cells. Strikingly, T cells 
from cDysM mice produced larger amounts of IL-17A and IFN-γ than T cells 
from SPF-1 and cSPF-2 mice (Figure 2.16D) both during steady state and 
colitis. Notably, TNF-α production after restimulation of T cells was highest 
during colitis in mice colonized with SPF-2 (Figure 2.16D).  
To further investigate the ability of the DysM to drive T cell-mediated intestinal 
inflammation, we transferred CD45RB(high)Foxp3-CD4+ T cells from IL-
17AGFPIFN-γKatushka FoxP3RFP triple reporter mice into SPF-1, cSPF-2 and 
cDysM Rag2-/- mice.   
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Figure 2.17 DysM, but not SPF-2 can enhance T-cell driven colitis severity. 
(A-F) T cell transfer colitis was induced by injecting CD4+Foxp3-CD45RB(high) T cells into 
SPF-1, cDysM or cSPF-2 Rag2-/- recipients. Body weight was measured after T cell transfer 
(A). Colonoscopy severity score at d14 post transfer (B). On d16 post injection mice were 
sacrificed. Colon weight/length ratio (C) was measured. Frequencies (D) and total numbers 
(E) of CD4+ cells in cLPL were monitored by FACS. Infiltration of different cytokine producing 
cell population in colon is displayed (F). Data represent n=7-16 mice/group as mean ± SEM 
from at least two independent experiments. P values indicated represent a nonparametric 
Kruskal-Wallis test *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 0,0001. 
 
Already after two weeks, when mice differed only mildly in their weight loss 
(Figure 2.17A), we observed already significantly higher intestinal 
inflammation as quantified by colonoscopy in cDysM compared to SPF-1 and 
cSPF-2 recipients (Figure 2.17B). Accordingly, cDysM mice displayed an 
enhanced colon weight to length ratio and cellular infiltration (Figure 2.17C 
2.17D and 2.17E). Specifically, IFN-γ+ CD4+ T cells numbers were 
significantly increased (Figure 2.17F). While numbers of IL-17A+ and double 
cytokine producing T cells were also significantly enhanced in cDysM 
colonized mice, their total numbers were much lower than those of IFN-γ+ 
CD4+ T cells (Figure 2.17F). Taken together, this demonstrates that the DysM 
induces pathogenic CD4+ T cells producing high levels of proinflammatory 
cytokines. Moreover, these microbiota-induced cells are essential to drive 
disease in two distinct colitis models.   
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2.4.7 Recognition of antigens from dominant microbial members by 
CD4+ T cells drives DSS colitis severity in DysM mice 
 
 
Figure 2.18 Antigen recognition by CD4+ T cells is indispensible for DysM, 
but not SPF-2 driven colitis. 
(A-B) SPF-1 WT and OTII transgenic mice were cohoused with DysM donor mice and DSS 
colitis was induced. Analysis of β-diversity (PCoA) of fecal microbiota is shown (A). Body 
weight (B) and intestinal inflammation by measuring colon length (C) and histology (D) on d5 
of DSS colitis were monitored. Representative pictures of H&E-stained colon sections, bar 
represents approx. 50µm. (E-F) DSS colitis was induced in SPF-1 and cSPF-2 WT and OTII 
transgenic mice and body weight was monitored for 10 days. Data represent n=5-20 
mice/group as mean ± SEM from at least two independent experiments. P values indicated 
represent a unpaired Student’s t test *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 0,0001. 
 
Intestinal CD4+ T cells recognize diet-derived and microbial antigens and this 
process is important in intestinal homeostasis and inflammation. To 
investigate whether recognition of microbial antigens by CD4+ T cells is 
required for exacerbation of colitis in DysM mice, DSS colitis was induced in 
OT-II transgenic mice colonized with the SPF-1, cSPF-2 or cDysM 
communities (Figure 2.18A). Strikingly, cDysM OT-II mice did not display 
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exacerbation of DSS colitis severity as indicated by the lack of DysM transfer 
induced changes in body weight loss, intestinal inflammation and colon 
shortening (Figure 2.18B, 2.18C and 2.18D). In contrast, cSPF-2 OT-II mice 
were characterized by similar weight loss compared to cSPF-2 WT mice 
(Figure 2.18E and 2.18F). This shows that antigen-specificity of CD4+ T cells 
is required for modulation of disease-severity by the DysM but not SPF-2 
communities.  
While both DysM and SPF-2 communities trigger severe colitis in the host the 
mechanisms of pathogenesis are completely opposing. Consequently, we 
wanted to understand whether triggering of innate or adaptive immunity by the 
SPF-2 or DysM communities dominates over each other when cotransferring 
them into SPF-1 recipients. Analysis of microbiota composition in recipient 
mice after cohousing of SPF-1 recipient as well as SPF-2 and DysM donor 
mice showed that the resulting community largely resembled the cDysM 
community (Figure 2.19A). Accordingly, host gene expression signatures in 
cDysM+SPF-2 mice were similar to the ones observed in cDysM mice 
including upregulation of genes associated with T cell, B cell, cytokine and 
chemokine signaling as well as upregulation of Cd4 (Figure 2.19B, 2.19C, 
2.19D, and 2.19E). Moreover, mice with cDysM+SPF-2 displayed high weight 
loss, intestinal inflammation, colon shortening and mortality compared to SPF-
1 mice (Figure 2.19F, 2.19G and 2.19H). Strikingly, the cDysM+SPF-2 
community failed to induce severe colitis in CD4-/- mice (Figure 2.19I, data not 
shown). These results demonstrate that the DysM community and its 
pathogenesis mechanism, i.e. the induction of pathogenic antigen-specific 
CD4+ T cell responses, dominates over SPF-2 induced changes during colitis 
induction.  
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Figure 2.19 CD4+ T cells drives DSS colitis severity in DysM mice by 
recognizing antigens from dominant microbial members. 
(A-I) SPF-1 WT mice were cohoused with DysM, SPF-2 or both DysM and SPF-2 donor mice, 
respectively. β-diversity analysis (PCoA) of fecal microbiota (A). RNAseq analysis was done 
from total colonic tissue. Heatmap shows quantification of RNA reads (B) and DEseq analysis 
to identify significant up/down-regulation (fold change >2) of genes in SPF-1 and 
cDysM+SPF-2 conditions (C). Pathway analysis based on GO terms of genes significantly 
upregulated (2-fold) in cDysM+SPF-2 compared to SPF-1 mice (D). Relative Cd4 expression 
in colonic tissue (E). After induction of DSS colitis in WT mice body weight loss and survival 
was monitored (F) and intestinal inflammation was measured by colon shortening (G) and 
histological analysis (H). Representative pictures of H&E-stained colon sections. Bar 
represents approx. 50µm. SPF-1 CD4-/- mice were cohoused with DysM and SPF-2 donor 
mice and DSS colitis was induced (I). Data represent n=5-12 mice/group as mean ± SEM 
from at least two independent experiments. P values indicated represent an unpaired 
Student’s t test. *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 0,0001. 
Chapter 2 
 
 
 78 
2.5 Discussion 
 
The incidence of IBD, a pathological immune response against microbial and 
environmental antigens, is gradually rising in developed countries, but no 
specific curative therapies exist. While several new therapies have been 
introduced in the past years, it remains to be investigated, which subgroups of 
IBD patients will benefit from these novel drugs 42. Alterations in the 
microbiome have been hypothesized to contribute to the development of IBD 
and patient data suggests the existence of microbial signatures associated 
with specific disease entities such as CD 6,37. However, it remains in question 
whether those changes are causal and can be potentially used to improve 
selection of IBD therapy or rather are the result of ongoing inflammation that 
alters the intestinal microenvironment 43. Here we identified and then 
characterized distinct types of microbial communities that directly affect the 
severity of intestinal inflammation in an immunocompetent host. We showed 
that these communities alter disease susceptibility via opposing mechanisms, 
one requiring antigen-specific CD4+ T cell responses and the other being 
mediated by innate immune cells (Figure 2.20). Our results provide novel 
insight into host-microbiota interactions directly responsible for altering 
susceptibility to IBD and suggest that microbiome signatures could be 
employed to predict disease pathogenesis. 
Healthy human individuals can differ greatly in the composition of their 
intestinal microbiota, but despite this variability alterations in the microbiota of 
patients have been associated with different types of human diseases 8,9. 
Germfree mice have been fundamental to address the causal role of 
alterations of the microbiome in mouse models of human disease. Likewise, 
conventionally housed laboratory mice that feature tremendous differences in 
the microbiome represent a valuable resource to study the contribution of 
diverse microbial ecosystems to disease development 44. But the observed 
variability within conventionally housed mouse lines requires sophisticated 
experimental planning to control and document this potentially cofounding 
factor in animal studies. In a first effort to reduce experimental variability, the 
concept of specific pathogen free housing conditions was introduced to 
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exclude unwanted influences imposed by the presence of potential pathogens 
such as Helicobacter spp. or mouse norovirus commonly present in wild and 
conventionally housed mice 44. Yet, microbiota composition differs greatly 
between SPF mice from different commercial breeders and academic 
institutions 45 and those differences influence host responses, e.g. the 
presence of Th17 cells in SFB colonized mice 36 or the lowered susceptibility 
to malaria infection as a consequence of increased abundance of 
Lactobacillaceae and Bifidobacteria 46. These observations also make 
genetically identical SPF mice a versatile experimental model to explore 
diverse microbial communities and to study host - microbiota interactions in 
health and disease. 
A common feature in IBD, particularly in UC, is an impairment of the intestinal 
barrier resulting in enhanced exposure to luminal microbes. By employing a 
mouse model of damage to the intestinal barrier, DSS colitis, we demonstrate 
that isogenic SPF mice with differences in microbiome composition feature 
altered susceptibility to intestinal inflammation. These alterations in colitis 
susceptibility were reminiscent of the dominant effects exerted by the 
microbial communities observed in conventionally housed Nlrp6 
inflammasome deficient mice (DysM)20. Specifically, we noted that transfer of 
colitogenic communities into mice relatively resistant to induction of DSS 
colitis is sufficient to alter disease susceptibility even in immunocompetent 
mice. Upon induction of disease, both the DysM community, as well as the 
SPF-2 community, induced severe colitis compared to the relative resistant 
SPF-1 community, yet, the mechanisms of pathogenesis differed strongly. 
While macroscopic characterization of inflammation did not reveal significant 
differences in mice with colitogenic communities, measurements of cytokine 
and chemokine signatures, as well as immunophenotyping, revealed large 
differences. Inflammation in SPF-2 mice was characterized by high levels of 
TNF-α and neutrophil-attracting chemokines coinciding with significant higher 
infiltration of neutrophils into the inflamed tissue. In line with previous findings, 
DysM mice featured higher levels of the chemokine CCL5, known to attract 
innate and adaptive immune cells carrying CCR1, CCR3, CCR4 and CCR5 20. 
Here, we identified high infiltration of activated CD4+ T cells in DysM mice 
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hinting towards a potential involvement of these cells in the intestinal 
pathogenesis. The hypothesis of adaptive immune cells being involved in 
DysM mice was further corroborated by the observation that extended 
colonization with the DysM, but not SPF-2 community, was required to 
transfer the disease susceptibility. Subsequently, we evaluated the effect of 
the transfer of the two colitogenic communities in mice lacking specific 
subsets of adaptive immune cells. For these comparisons we employed WT 
and gene-deficient mice that were embryo-transferred into our vivarium using 
SPF-1 foster mothers resulting in a standardized microbiota (Galvez E et al., 
manuscript submitted). Moreover, we included cohousing of WT and gene-
deficient mice to further reduce microbiota variability within experiments and 
documented for all experiments microbiota composition using 16S rRNA 
sequencing. Using this carefully controlled approach, we observed significant 
increases in IL-17A and IFN-γ secretion by CD4+ T cells during DysM and 
SPF-2 driven colitis. Notably, this is in line with an association of CD4+ T cells 
and proinflammatory cytokines including IL-17, IFN-γ, and IL23 with human 
IBD 1. Strikingly, our experiments demonstrated that CD4+ T cells are only 
essential to mediate the exacerbation of DSS colitis in DysM but not SPF-2 
mice. In contrast, despite measurable CD4+ T cell activation during DSS 
colitis, SPF-2 modulated disease severity independent of adaptive immune 
cells. TCR mediated recognition of cognate antigens is required for proper T 
cell function and recognition of microbial antigens has been suggested to 
significantly contribute to development of colitis 47. Using OTII transgenic mice 
we could show that DysM-driven but not SPF-2-driven colitis development 
strongly depended on the presence of antigen-specific CD4+ T cells. The 
presence of in vivo cytokine secreting CD4+ T cells already before induction 
of DSS colitis in DysM mice suggests that colonic CD4+ T cells recognize 
cognate microbial antigens already during this phase, similar to what has 
been observed for SFB-specific CD4+ T cells in the small intestine 48. 
Importantly, antibody-mediated depletion of CD4+ T cells during colitis 
resulted in failure to transfer enhanced colitis susceptibility. This 
demonstrated that to enhance colitis modulation of the mucosal barrier by 
CD4+ T cells in the steady state was not sufficient and rather required the 
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presence and presumably the effector functions of CD4+ T cells during colitis. 
The distinct property of the DysM community to prime and activate pathogenic 
CD4+ T cell responses was further corroborated using a model for CD4+ T 
cell-mediated colitis. Specifically, transfer of CD4+ T cells in Rag2-/- mice 
harboring the DysM but not the SPF-2 microbiota enhanced intestinal 
inflammation and cytokine production by CD4+ T cells. Together this shows 
that colitogenic communities exert their pathogenic effects in the same 
disease model by opposing mechanisms (Figure 2.20).  
 
 
Figure 2.20 Distinct microbial communities drive colitis via opposing 
pathways. 
Already at baseline, colonization with distinct microbial communities exerts different host 
immune responses in the intestinal mucosa (steady state). When both SPF-1 and SPF-2 
community do not show any host responses, DysM colonization results in increased CD4+ T 
cell infiltration. Upon trigger with DSS, distinct microbial communities drive colitis via different 
pathways (DSS). SPF-1 community drives a mild colitis and both SPF-2 and DysM 
communities drive severe colitis. However, SPF-2 colitis enhancement is characterized by 
infiltration of neutrophils and associated chemokines, whereas, DysM mediated colitis 
requires antigen specific CD4+ T cells to enhance disease severity. 
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Different models have been proposed to explain the contribution of the 
microbiota to the development of IBD and other complex diseases. On one 
hand, specific members of the microbiota, so called pathobionts, have been 
proposed to play essential roles, i.e. their presence is sufficient to induce 
disease similar to the “one-microbe – one-disease” concept. Detailed 
characterization of the colitogenic communities using 16S rRNA sequencing 
revealed the varying presence of potential pathobionts such as SFB, 
Prevotella spp., Helicobacter spp., Enterobacteriaceae and 
Verrucomicrobiaceae in DysM and SPF-2 mice. SFB have been shown to 
modulate intestinal T cell immunity and systemic autoimmunity 36. But, based 
on its presence in both SPF-2 and DysM mice, a role in driving the differential 
requirement for CD4+ T cells can be excluded. Similarly, members of the 
genus Prevotella, previously found to be enriched in the colitogenic microbiota 
of Nlrp6-/- mice 20, were present in both colitogenic communities indicating that 
they are not involved in regulating the different pathogenicity modes. 
Helicobacteriaceae have been demonstrated to induce the development of 
colitis in Il10-/- mice 13. Notably, monocolonization of germfree Il10-/- mice with 
H. hepaticus failed to induce colitis, moreover, in some colonies of Il10-/- mice 
H. hepaticus colonization did not cause colitis, demonstrating that the ability of 
H. hepaticus and potentially other members of this family to induce colitis 
seems to depend very strongly on the composition of the microbiota. While 
Helicobacterceae were absent in SPF-2 mice, DysM mice harbored different 
members of this family including H. typhlonius, H. rodentium and H. 
muridarum, but did not harbor H. hepaticus. The role of these bacteria in 
modulating severity of DSS colitis and triggering of specific T cell responses in 
immunocompetent hosts is unknown. Finally, both Enterobacteriaceae and 
Verrucomicrobiaceae, specifically Akkermansia muciphilia, bloomed during 
the induction of DSS colitis in SPF-2 mice, yet it is being debated whether 
expansion during disease suggests a contribution to disease development or 
rather a consequence of the ability to utilize inflammation-induced 
metabolites. In contrast to the “one-microbe-one disease” model the concept 
of dysbiosis, an imbalance of the community, has been proposed for 
microbiome-mediated modulation of diseases 49. One characteristic of 
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dysbiotic communities including those in IBD patients has been suggested to 
be an imbalance between Bacteroides, Firmicutes and Proteobacteria with an 
overexpansion of Bacteroides and Proteobacteria over Firmicutes 37. Lowered 
Firmicutes / Bacteroides ratios were noted in all colitogenic communities 
including SPF-2 and DysM, whereas the ratios between Firmicutes and 
Proteobacteria (F/P) was not consistently different between susceptible and 
resistant groups. Notably, the F/P ratio was the lowest in DysM mice and 
according to our data this is associated with a distinct mode of pathogenicity. 
Whether in the cases of the SPF-2 and DysM community specific pathobionts 
or a general dysbiosis are responsible for driving distinct pathogenicity 
requires further investigation. Meanwhile these colitogenic communities 
provide an innovative approach to dissect the immune pathways involved in 
microbiota modulated colitis development and to test whether the efficacy of 
novel immunomodulators is influenced by the microbiome. 
In summary, our data show how distinct microbial communities drive the 
development of intestinal inflammation in immunocompetent hosts by 
modulating opposing arms of the immune system. Our study suggests a 
concept that triggering of different immune pathways by microbial 
communities can alter disease susceptibility eventually resulting in similar 
host pathophysiology. This implies that a personalized immunomodulatory 
treatment according to distinct microbial signatures may be beneficial for IBD 
patients.  
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CHAPTER 3 
 
Cytokine knock-in reporter mice demonstrates SFB-
dependent bystander effect on intestinal distinct CD4+ 
T cell subsets upon Salmonella infection 
 
3.1 Summary 
 
The mucosal immune system plays an essential role to protect the host 
against infections. Recent studies have established that in the gastrointestinal 
(GI) tract, the gut microbiota as a community contributes to antimicrobial 
immunity through modulation of innate and antigen-specific mucosal immune 
responses. However, which specific members of these diverse intestinal 
microbial communities are responsible for the immunomodulatory effects is 
less well understood. The best-studied bacterium, known as segmented 
filamentous bacteria (SFB), is a strong inducer of Th17 cells in the small 
intestine of mice during steady state. But, the diversity and functionality of 
SFB induced memory CD4+ T cells is still being debated. By employing novel 
gnotobiotic cytokine knock-in reporter mice (IL-17AGFP IL-22BFP FoxP3RFP) we 
confirm that SFB colonization in the ileum is sufficient to induce the 
differentiation of Rorγt+ Th17 cells that subsequently seed the large and small 
intestine. Notably, only in the terminal ileum these cells produce IL-17A even 
in the steady state, likely as consequence of recognizing cognate SFB-
derived antigens. Upon induction of intestinal inflammation by Salmonella 
Typhimurium infection, we observed IL-17A+IL-22+ and IL-17A-IL-22+ CD4+ 
T cells at early timepoints after infection only in the cecum of mice harboring 
SFB. Based on the enrichment of SFB-specific TCR Vβ chains in these 
“innate-like” CD4+ T cell subsets, we hypothesize that bystander activation 
induces cytokine production from microbiota-specific memory T cells rapidly 
after infection with enteropathogens. Supporting this conclusion, SFB 
monocolonization of germfree mice was sufficient to induce the appearance of 
similar subsets in steady state and after infection. Gene expression analysis
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 by RNAseq revealed distinct properties of SFB modulated T cell subsets in 
the steady and after infection including the differential expression of IL-17F 
and IFN-γ. Finally, SFB colonized mice displayed reduced pathogen invasion 
in the cecum suggesting that modulation of CD4 T cells by SFB is associated 
with improved immune defense. 
In summary, we demonstrate that SFB induces Th17 and other CD4+ T cell 
subsets in the steady state, which serve as “innate-like” source of numerous 
cytokines rapidly after infection. These findings provide new insight into the 
previously known role of SFB to shape CD4+ T cells and may have 
implications for patients suffering from GI diseases, which are characterized 
by diverse subsets of cytokine-producing CD4+ T cells in the intestine. 
 
3.2 Introduction 
 
Antigen-specific CD4+ T cells, which are part of the adaptive immune system, 
play pivotal roles during immune responses through their ability to differentiate 
into diverse subsets of T helper (Th) cells and to subsequently secrete potent 
immunoregulatory cytokines as well as to form long-lasting memory. Th17 and 
Th22 are two subsets of CD4+ T cells and involved in maintaining the balance 
between homeostasis and inflammation at mucosal sites. Th17 cells are 
characterized by their production of effector cytokines interleukin (IL)-17A, IL-
17F, IL-22 and function as important activators of innate immune effectors, 
thereby contributing to the mucosal defense against bacteria and fungi 1. 
Pathogenic roles of Th17 cells have also been described in different animal 
models of autoimmune disease including rheumatoid arthritis, psoriasis, 
multiple sclerosis and inflammatory bowel disease 2–5. In humans, Th22 cells, 
a newly classified CD4+ T cell subset distinct from Th17 cells due to their 
complete lack of IL-17A expression, are considered the major source of 
adaptive immune cell-derived IL-22 6. IL-22 confers both proinflammatory 
and/or tissue protective functions based on type of inflammatory response, 
cellular source and surrounding cytokine milieu 7,8. Studies performed in 
different in vivo and in vitro models have shown a high heterogeneity of both 
Th17 and Th22 cell subsets characterized by the variable production of 
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additional immunomodulatory cytokines such as IFN-γ and IL-10. The variable 
impact of these cell subsets on the outcome of different disease models is 
likely related to their heterogeneity. Therefore, detailed studies are needed to 
identify the instructive networks as well as both molecular and functional 
properties of potentially heterogenous Th17 and Th22 cell subsets. 
The making of lineage-decisions during T cell differentiation is heavily 
influenced by environmental stimuli. In the gastrointestinal (GI) tract hundreds 
of distinct species of microorganisms constantly convey signals to the host 
mucosal immune system. However, it is evident now that only specific 
members of the intestinal microbiota are able to induce antigen-specific helper 
CD4+ T cells in absence of a classical infection. The best-known example is a 
bacterium known as segmented filamentous bacteria (SFB), which is closely 
related to family Clostridiaceae and induces the maturation of the mucosal 
immune system in the small intestine, e.g. it drives the differentiation of Th17 
cells 9. A further study demonstrated that SFB-triggered cascade, in which 
innate lymphoid cell (ILC) -3 secretion of IL-22 is crucial for production of 
serum amyloid A (SAA) proteins 1 and 2 from intestinal epithelium resulting 
Th17 induction 10. Notably, a diverse set of other intestinal bacteria with the 
ability to attach to the epithelium has been demonstrated to induce Th17 cell 
differentiation 11. In addition to the classical antigen-dependent activation of T 
cells, bystander activation, i.e. the stimulation of unrelated T cells by cytokines 
during an immune response or inflammation, has emerged as potent 
activation mechanism of tissue-resident memory cells 12. Specifically, 
protection mediated by SFB-induced Th17 cells during C. rodentium infection 
has been hypothesized to occur upon bystander activation. Recently we were 
able to show that specific members of the microbiota induced enhancement of 
IFN-γ production by CD4+ T cells, which contributed to resistance of mice 
against Salmonella infection 13. While these results provide more evidence for 
the impact of the microbiota on CD4+ T cells in the intestine, it is not known 
yet, whether CD4+ T cells and specifically Th17 and Th22 cells primed by 
intestinal microbiota produce the same effector cytokines during antigen-
induced and bystander activation in vivo.  
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Th17 and Th22 cells have been characterized in detail in vitro, however, 
technical difficulties such as the inability to determine gene expression profiles 
after ex-vivo restimulation and fixation of the cells have precluded a detailed 
ex vivo characterization of effector functions and diversity. Here, we have 
employed transgenic mouse lines, in which the expression of a fluorescent 
protein is under control of the endogenous promoter of a transcription factor 
or cytokines, i.e. FoxP3, IL-17A, and IL-22. These mouse lines allow the 
isolation of intact transcription factor or cytokine-expressing cells ex vivo 
based on their expression of individual or combinations of fluorescent 
proteins. Using these mouse lines, we characterized CD4+ T cell subsets 
induced either by the microbiota and as control activated during inflammation. 
Our novel data demonstrated that presence of SFB in the intestinal microbiota 
result in bystander activation of IL-17A and IL-22 producing CD4+ T cells 
upon Salmonella Typhimurium infection and can provide protection from 
colonization of the pathogen in intestinal tissue. Investigation of gene 
expression profiles by low-input RNAseq revealed distinct properties of these 
SFB modulated bystander activated T cell subsets compared to antigen-
activated T cells including differential expression of IL-17F and IFN-γ. Notably, 
recent studies using multi-parameter flow cytometry have shown the presence 
of numerous tissue-specific Th cell subsets with distinct cytokine expression 
throughout the intestine and numerous other tissues in human body 14. 
Hence, characterizing the diversity of CD4+ T cell responses and particularly 
Th17 and Th22 responses induced by the microbiota will be essential to 
understand the contribution of microbiota-induced memory T cells to host 
pathophysiology. 
 
 
3.3 Experimental procedures 
 
Mice: Wild type and all transgenic mice, IL-17AGFP IL-22BFP FoxP3RFP, 
RORγtGFP FoxP3RFP, IL-17AGFP IFN-γKatushka FoxP3RFP and IL-17AGFP IL-
22BFPIFN-γKatushka FoxP3RFP reporter mice used in the study were on 
C57BL/6N background and have been rederived into SPF-1 microbiota by 
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embryo transfer and bred at the specific pathogen free animal facilities of 
Helmholtz Centre for Infection Research (HZI). SFB-monocolonized NOD/scid 
mice were bred in gnotobiotic isolators at the Medical University Hannover, 
Germany. Colonization with SFB was achieved by cohousing or oral gavage 
with intestinal content from SFB-monocolonized mice at least four weeks 
before infection experiments. Germ-free C57BL/6NTac mice were bred in 
isolators (Getinge) in the germ free facility of the HZI. All experiments were 
performed with 8-12 weeks old age-matched and gender-matched animals. 
Both male and female animals were used for every experiment to exclude 
influence of gender. 
 
Colitis model induced by infection with S. Typhimurium: Naturally 
streptomycin-resistant wild-type strain S. enterica serovar Typhimurium 
SL1344 and isogenic mutant ΔAroA were used. Salmonella strains were 
grown overnight at 37°C in Luria-Bertani (LB) broth, with either 50µg/ml 
kanamycin or 100µg/ml streptomycin, then, diluted 1:100 in fresh medium, 
and subcultured for 4 hours. Bacteria were washed twice in ice-cold 
phosphate-buffered saline (PBS) and then used for infection experiments. 
Water and food were withdrawn for 4 hrs before mice were treated with 20 mg 
/ mouse of streptomycin by oral gavage (o.g.). Afterwards, mice were supplied 
with water and food ad libitum. 20 hrs after streptomycin treatment, water and 
food were withdrawn again 4 hrs before the mice were infected with 105 CFU 
of S. Typhimurium and 3x106 CFU of ΔAroA in 200 µl PBS. Drinking water ad 
libitum was supplied immediately and food 2 hrs post infection (p.i.). Mice 
were weighted every day and survival was monitored.  
 
Analysis of bacterial loads in intestinal content and systemic organs: All 
mice were euthanized by asphyxiation with CO2 and cervical dislocation at 
indicated time points. Intestinal tissues (small intestine, cecum, colon) and 
organs (mesenteric lymph nodes, spleen) were removed aseptically. To 
collect fecal content, organs were flushed with sterile PBS. Organs were 
opened longitudinally, cleaned thoroughly with sterile PBS and weighted. 
Organs and content were homogenized in sterile PBS using a Polytron 
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homogenizer (Kinemtatica). Dilutions of homogenized samples were plated on 
LB plates containing 50 µg/ml Kanamycin or 100µg/ml streptomycin and 
incubated overnight at 37°C to determine CFUs.  
 
Analysis of SFB loads from content and tissue: Fresh stool samples of 
mice were collected and immediately stored at -20°C. DNA was extracted 
according to established protocols using a method combining mechanical 
disruption (bead-beating) and phenol/chloroform-based purification 15. Briefly, 
sample was suspended in a solution containing 500µl of extraction buffer (200 
mM Tris, 20mM EDTA, 200mM NaCl, pH 8.0), 200µl of 20% SDS, 500µl of 
phenol:chloroform:isoamyl alcohol (24:24:1) and 100µl of 0.1 mm 
zirconia/silica. Samples were homogenized twice with a bead beater 
(BioSpec) for 2 min. After precipitation of DNA, crude DNA extracts were 
resuspended in TE Buffer with 100µg/ml RNase and column purified to 
remove PCR inhibitors (BioBasic). Quantitative PCR was performed to detect 
total bacteria and SFB using specific primer sets: 16S (F: 5’- 
ACTCCTACGGGAGGCAGCAGT and R: 5’- ATTACCGCGGCTGCTGGC) 
and SFB (F: 5’- GACGCTGAGGCATGAGAGCAT and R: 5’- 
GACGGCACGGATTGTTATTCA). 
 
Isolation of colonic lamina propria leukocytes (cLPL) and flow 
cytometry: To isolate cLPL, density gradient centrifugation using Percoll was 
done as previously described 16. In brief, colons were collected during steady 
state and at d5 of DSS treatment. Fecal content was removed, tissues were 
opened longitudinally, washed with PBS and then shaken in HBSS containing 
2 mM EDTA for 20 min at 37°C. Tissues were cut into small pieces and 
incubated with digestion solution (DMEM containing 1% fetal bovine serum 
(FBS), 0.25 mg/ml collagenase D, 0.5 U/ml dispase and 5 μg/ml DNase I) in 
a shaker for 20 min at 37°C. Digested tissues were filtered through 70uM cell 
strainer (Falcon) and DMEM + 5% FBS was added to inactivate enzymes. 
The last two steps were repeated until all tissue was digested. After 
centrifugation, cells were resuspended in 4 ml of 40% Percoll (GE Healthcare) 
and overlaid on 4 ml of 80% Percoll. Percoll gradient separation was 
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performed by centrifugation at 450 g for 25 min at 25°C. Cells in the 
interphase were collected and used as LPL. The collected cells were then 
suspended in staining buffer containing PBS, 1% FBS and 2 mM EDTA. The 
following antibodies were used: anti-CD45 (30-F11), anti-CD3 (17A2), anti-
CD4 (RM4-5, GK1.5), anti-CD8a (53-6.7), anti-TCRγδ (GL3), anti-CD44 (IM7), 
anti-CD62L (MEL-14), anti-CCR6 (29-2L17) (Biolegend) and anti-Vβ-14 (14-2) 
(BD Bioscience). To distinguish live dead cells AlexaFluor-350 NHS Ester 
(Life Technologies) was used. Flow cytometry analysis was performed using a 
BD LSR (BD Biosciences) and data were analyzed with FlowJo software 
(TreeStar Inc.). 
 
RNA isolation and quantitative PCR: Tissues were preserved in RNAlater 
solution (Ambion) and subsequently homogenized in Trizol reagent 
(Invitrogen). One microgram of total RNA was used to generate cDNA by the 
protocol for first strand cDNA synthesis using RevertAid RT (Thermo 
Scientific). RealTime-PCR was performed using gene-specific primer sets 
(Sigma) of Il17a primer (F: 5’- ACGTTTCTCAGCAAACTTAC and R: 5’- 
CCCCTTTACACCTTCTTTTC); Il17f primer (F: 5’- 
ATACCCAGGAAGACATACTTAG and R: 5’- AGTCCCAACATCAACAGTAG); 
primer sets (Life Technologies) Ifng primer (Mm00801778_m1); Il22 primer 
(Mm04203745_mH) and Kapa Sybr Fast or Probe qPCR kit (Kapa 
Biosystems) on a LightCycler 480 instrument (Roche). PCR conditions were 
950C for 60 s, followed by 40 cycles of 950C for 3 s and 600C for 30 s. Data 
were analyzed using the the deltaCt method with hprt (F: 
CTGGTGAAAAGGACCTCTCG and R: 
TGAAGTACTCATTATAGTCAAGGGCA) serving as the reference 
housekeeping gene. 
 
Low-input RNA sequencing: A minimum of 1000 cells was sorted and RNA 
was isolated using the RNAeasy plus micro Kit (Qiagen). RNA samples were 
used to synthesize and amplify cDNA (SmartSeq v4 3’ DE Kit, Takara) 
followed by DNA library preparation for sequencing (Nextera XT, Illumina). 
This approach allowed us to multiplex up to 12 samples / HiSeq run. We 
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employed an analysis pipeline to determine differentially expressed genes. 
Briefly, raw reads were quality filtered using Trimmomatic and aligned to the 
mouse reference genome (mm10) using STAR. Normalization and differential 
expression were quantified using the DEseq2 package. Differential expressed 
gene networks were analyzed using the Consensus Path DB-mouse 
webserver. 
 
Field emission scanning electron microscopy (FESEM): Gut samples 
were fixed with 5% formaldehyde and 2% glutaraldehyde in HEPES buffer 
(0.1 M HEPES, 10 mM CaCl2, 10 mM MgCl2 and 0.09 M sucrose, pH 6.9) 
overnight at 7°C, then washed twice with TE buffer (20 mM TRIS, 2 mM 
EDTA, pH 6.9) and gut content was squeezed out. Dehydration was achieved 
with a graded series of acetone (10, 30, 50, 70, 90, 100%) on ice for 15 min 
for each step. Samples in the 100% acetone step were allowed to reach room 
temperature before another change in 100% acetone. Samples were then 
subjected to critical point drying with liquid CO2 (CPD 300, Leica, Wetzlar). 
Dried samples were covered with a gold-palladium film by sputter coating 
(SCD 500 Bal-Tec, Liechtenstein) before examination in a field emission 
scanning electron microscope Zeiss Merlin (Oberkochen) using the Everhart-
Thornley SE-detector and the Inlens SE-detector in a 40:60 ratio with an 
acceleration voltage of 5 kV. 
 
Statistical analyses: Statistical analysis was performed using GraphPad 
Prism program (GraphPad Software). Data are expressed as mean ± SEM. 
Differences were analyzed by Student’s t test and ANOVA. P values indicated 
represent a non-parametric Mann-Whitney U test or Kruskal-Wallis test 
comparison between groups. P values ≤ 0.05 were considered as significant: 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
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3.4 Results 
 
3.4.1 CD4+ T cells are the central source of in vivo IL-17A and IL-22 
production upon enteric infection 
 
The cytokines IL-17A and IL-22 play crucial roles during homeostasis and 
inflammation and are produced by various cell types during mucosal 
inflammation. To assess in situ production of these cytokines we took 
advantage of a novel IL-17AGFP IL-22BFP Foxp3RFP triple reporter mouse line 
(S. Huber, unpublished data). Specifically, we investigated the source of in 
vivo IL-17A and IL-22 production during steady state conditions as well as at 
early time points after Salmonella Typhimurium infection. Therefore, we 
infected streptomycin-pretreated IL-17AGFP IL-22BFP Foxp3RFP mice raised 
under conventional housing conditions with S. Typhimurium (S. Tm.) or left 
them untreated (steady state) and then isolated leukocytes from intestinal 
lamina propria (LPL) and lymphoid organs 20 hrs post infection (p.i.) (Figure 
3.1A). 
 
 
Figure 3.1 In-vivo IL-17A and IL-22 production in small intestine. 
Experimental procedure for infection with Salmonella enteria serovar Typhimurium (S. Tm.), 
briefly Streptomycin-pretreated mice were orally infected with 105 of S. Tm. (A). Laminar 
propria leukocytes (LPL) were isolated from small intestine of non-infected (Steady state) and 
20h after S.Tm. (S.Tm. 20h p.i.) infected IL-17AGFP IL-22BFP Foxp3RFP (conventionally raised) 
mice. Representative FACS plots are shown for IL-17A and IL-22 production from different 
cell subsets (B). Data represent n=4-6 mice/group from at least two independent experiments. 
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In vivo IL-17A production in mice during steady state was in small intestinal 
and cecal LPLs mainly derived from CD3+CD4+ T cells, likely reflecting the 
presence of SFB in our conventional mouse facility (Figure 3.1B, 3.2A). 
Notably, since S. Tm. induces inflammation mainly in the cecum in vivo IL-
17A production from CD3+CD4+ small intestinal LPLs was not altered after 
infection with S. Tm (Figure 3.1B).  
 
 
Figure 3.2 In-vivo IL-17A and IL-22 production in cecum. 
LPL were isolated from cecum of non-infected (Steady state) and 20h after S.Tm. (S.Tm. 20h 
p.i.) infected IL-17AGFP IL-22BFP Foxp3RFP (conventionally raised) mice. Representative FACS 
plots are shown for IL-17A and IL-22 production from different cell subsets (A). Frequencies 
and absolute numbers of IL-17A and/or IL-22 production from CD3+CD4+ cells (B). Relative 
contribution of different leukocyte subsets for total production of IL-17A and IL-22 single or 
double cytokines (C). Data represent n=4-6 mice/group as mean ± SEM from at least two 
independent experiments. P values indicated represent a unpaired Student’s t test *p < 0,05; 
**p < 0,01; ***p< 0,001; ****p< 0,0001. 
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In contrast, direct in situ IL-22 production was detected mainly in cecal LPLs 
in infected mice, but absent under steady state conditions. Strikingly, 
CD3+CD4+ cells were the major in vivo source of IL-17A single and IL-17A/IL-
22 double cytokine production in LPL from infected cecum (Figure 3.2A, 3.2B 
and 3.2C). Although CD3-CD4- cells were the main source of IL-22 single 
cytokine production in cecum, CD3+CD4+ production of IL-22 increased 
significantly after Salmonella infection (Figure 3.2C).  
 
 
Figure 3.3 In-vivo IL-17A and IL-22 production in lymphoid organs. 
Leukocytes were isolated from mesenteric lymphnodes and Peyer’s patches of non-infected 
(Steady state) and 20h after S.Tm. (S.Tm. 20h p.i.) infected IL-17AGFP IL-22BFP Foxp3RFP 
(conventionally raised) mice. Representative FACS plots are shown for IL-17A and IL-22 
production from different cell subsets (A). Data represent n=4-6 mice/group from at least two 
independent experiments. 
 
Similarly, distinct lymphocytes subsets isolated from both mesenteric 
lymphnodes and Payer’s patches demonstrated no in vivo IL-22 production 
(Figure 3.3A). Only IL-17A production was observed from CD3+CD4+ cell 
subsets from these lymphoid organs, however no major difference was 
detected between infected and non-infected groups (Figure 3.3A). Together, 
these data suggest that, CD4+ T cells are a significant source of early in vivo 
IL-17A and IL-22 responses in the intestinal mucosa after Salmonella 
infection. 
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3.4.2 In vivo early IL-17A/IL-22 response by CD4+ T cells upon 
Salmonella infection are dependent on SFB 
 
 
Figure 3.4 SFB colonization results in induction of only in-vivo IL-17A 
producing CD3+CD4+ cells in small intestine. 
(A-C) eSPF IL-17AGFP IL-22BFP FoxP3RFP reporter mice mice were cohoused with SFB 
monocolonized mice. SFB colonization was detected by scanning electron microscopy of 
terminal ileum (A). SFB colonization in tissue (B) and intestinal content (C) was quantitatively 
assessed by qPCR. 
(D-E) LPL were isolated from IL-17AGFP IL-22BFP FoxP3RFP mice harboring only eSPF or eSPF 
cohoused with SFB monocolonized mice (eSPF+SFB) during steady state. Gating strategy to 
characterize distinct LPL subsets is given (D). Representative FACS plots showing different 
subsets of LPLs gated on CD45+ cells releasing IL-17A and/or IL-22 in-vivo (E). 
Data represent n=4-13 mice/group as mean ± SEM from at least two independent 
experiments. P values indicated represent a unpaired Student’s t test *p < 0,05; **p < 0,01; 
***p< 0,001; ****p< 0,0001. 
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Previous work has demonstrated that innate-like Th17 responses upon 
enteropathogenic infection are dependent on the intestinal microbiota 12. To 
confirm this prior observation and further investigate the effect of the 
microbiota on in vivo cytokine production, we rederived IL-17AGFP IL-22BFP 
Foxp3RFP mice into an enhanced specific pathogen free (eSPF) microbiota 
condition lacking numerous known immunomodulatory components of 
microbiota, i.e. SFB, Helicobacter spp., norovirus and Tritrichomonas spp. 
that have been reported to influence CD4+ T cell responses. Specifically, SFB 
is known to induce Th17 response. To determine the influence of SFB on the 
Salmonella induced early CD4+ T cell response, we therefore cohoused our 
eSPF reporter mice with SFB monoassociated donor mice for 14 days. 
Scanning electron microscopy of the terminal ileum of SFB cohoused 
recipients demonstrated the presence of long segmented bacteria attached to 
the epithelium of SFB cohoused mice, which were absent in eSPF mice 
(Figure 3.4A). In addition, we characterized SFB colonization associated to 
the mucosa as well as in the lumen by performing SFB-specific qPCR. As 
expected SFB was enriched in the mucosa of the terminal ileum, but 100-fold 
decreased levels were detected associated with both the cecal and colonic 
mucosa of SFB-cohoused mice compared to SFB-deficient mice (Figure 
3.4B). Notably, despite its enrichment in the mucosal fraction, SFB was also 
detected in the intestinal content in both SI and colon (Figure 3.4C). Next, we 
characterized different immune cells producing IL-17A/IL-22 from eSFP 
reporter mice in presence or absence of SFB during steady state (Figure 
3.4D). In line with previous studies we observed significant increases in the 
frequency and number of IL-17A producing CD3+CD4+ T cells in vivo from 
small intestinal lamina propria of eSPF mice colonized with SFB (Figure 
3.4E). Other distinct immune cell repertoire from small intestinal LPL and 
immune cells isolated from cecal LPL did not show any significant IL-17A/IL-
22 induction at baseline (Figure 3.4E).  
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Figure 3.5 In-vivo IL-17A and IL-22 production after Salmonella infection is 
induced by SFB. 
(A-C) LPL were isolated during 20h after S.Tm. infection from IL-17AGFP IL-22BFP FoxP3RFP 
mice harboring only eSPF or eSPF cohoused with SFB monocolonized mice (eSPF+SFB). 
Representative FACS plots showing different subsets of LPLs gated on CD45+ cells releasing 
IL-17A and/or IL-22 in-vivo (A). Percentage and absolute number of IL-17A and IL-22 single 
or double producing CD3+CD4+ T cells are shown from small intestine (B) and cecum (C). 
Data represent n=7-13 mice/group as mean ± SEM from at least two independent 
experiments. P values indicated represent a unpaired Student’s t test *p < 0,05; **p < 0,01; 
***p< 0,001; ****p< 0,0001. 
 
In contrast, infection with Salmonella pathogen induced a distinct cytokine 
milieu 20hrs post infection. Similar to conventionally housed mice, SFB 
colonized eSPF mice demonstrated significant increases in the frequencies 
and numbers of IL-17A-IL-22+ and IL-17A+IL-22+ CD4+ T cells in the cecal 
LPLs (Figure 3.5A, 3.5C). Interestingly, this increase of cytokine production 
was not observed in CD3+CD4- and CD3-CD4- cellular fractions of cecal 
LPLs (Figure 3.5A, 3.5C). Similar to steady state conditions the presence of 
SFB resulted in induction of only IL-17A production from CD3+CD4+ T cells in 
small intestinal LPL from Salmonella infected mice (Figure 3.5A, 3.5B). No 
additional cytokine production was observed in presence of SFB by distinct 
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subsets of small intestinal LPLs after Salmonella infection (Figure 3.5A, 3.5B). 
Notably, absolute numbers of these different cell populations supported the 
observation indicating SFB mediated increased absolute recruitment of these 
cells specifically IL-17A-IL-22+ and IL-17A+IL-22+ CD3+CD4+ T cells in the 
site of infection (Figure 3.5B, 3.5C).  
 
 
Figure 3.6 In-vivo IL-17A and IL-22 production in germ free (GF) mice. 
LPL were isolated during steady state and 20h after S.Tm. infection from IL-17AGFP IL-22BFP 
FoxP3RFP GF mice or GF cohoused with SFB monocolonized mice (GF+SFB). 
Representative FACS plots showing different subsets of LPLs gated on CD45+ cells releasing 
IL-17A and/or IL-22 in-vivo during steady state (A). Percentage and absolute number of IL-
17A and IL-22 single or double producing CD3+CD4+ T cells are shown from small intestine 
(B) and cecum (C). Data represent n=7-13 mice/group as mean ± SEM from at least two 
independent experiments. P values indicated represent a unpaired Student’s t test *p < 0,05; 
**p < 0,01; ***p< 0,001; ****p< 0,0001. 
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To exclude the effect of different food antigens and/or interaction of SFB with 
other members of the intestinal microbiota on our observations, we rederived 
IL-17AGFP IL-22BFP Foxp3RFP mice into germ-free (GF) conditions. Thereby, we 
could cohouse GF reporter mice with monoassociated SFB mice to monitor 
whether SFB is sufficient to induce these distinct cytokine producing cells in 
vivo. Similar to SFB cohoused eSPF mice, monoassociation of GF mice with 
SFB also resulted in significant production of IL-17A from small intestinal 
CD3+CD4+ LPLs at baseline (Figure 3.6A). Interestingly, in contrast to eSFP 
mice, cecal LPLs isolated from GF mice during steady state demonstrated 
increase in IL-17A production from CD3+CD4+ cells only in presence of SFB 
(Figure 3.6A). During infection with S. Tm., in line with the observations from 
the eSPF mice, we detected increased frequencies and absolute numbers of 
IL-17A-IL-22+ and IL-17A+IL-22+ CD4+ T cells in cecal LPLs from S. Tm. 
infected SFB colonized GF mice (Figure 3.6C). Unlike eSPF mice, S. Tm. 
infection resulted in robust accumulation of additional IL-17A+IL-22- 
CD3+CD4+ T cells in cecal LPL and IL-17A-IL-22+ and IL-17A+IL-22+ 
CD3+CD4+ T cells also in the small intestinal LPLs of GF mice harboring SFB 
(Figure 3.6B, 3.6C). CD3+CD4- and CD3-CD4- cells did not show any 
difference on in vivo cytokine production in presence or absence of SFB in GF 
mice (data not shown). Taken together, these data demonstrate that early 
production of IL-17A and IL-22 by CD4+ T cells after Salmonella infection 
require SFB priming.  
 
3.4.3 SFB-specific CD4+ T cells in the cecum obtain effector function of 
cytokine production upon Salmonella infection  
 
Both SFB induced Th17 cells and innate like Th17 cells have been reported to 
show activated memory-like phenotype 12. We characterized the activation 
and memory state of SFB-induced IL-17A and/or IL-22 producing CD3+CD4+ 
T cells based on the expression of specific markers including CCR6, CD44 
and CD62L in the presence or absence of Salmonella infection (Figure 3.7A, 
3.7B).  
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Figure 3.7 Characterization of SFB induced CD4+ T cells in eSFP mice using 
surface markers. 
(A-E) LPL were isolated during steady state and 20h after S.Tm. infection from IL-17AGFP IL-
22BFP FoxP3RFP mice harboring eSPF or eSPF+SFB. Representative plots showing 
expression of distinct surface markers from non-infected (left) and infected (right) animals of 
CCR6 (A) and CD44/CD62L (B) expression. Percentages of cytokine producing cells 
expressing distinct surface markers i.e. CD44hiCD62L- (Effector memory), CCR6 or 
CD44loCD62L+ (naïve) in small intestine during baseline (C), in small intestine and cecum 
during S.Tm. infection (D). Enrichment of Vβ14 TCR in IL-17A and IL-22 producing CD4+ T 
cells compared to non-cytokine producing CD4+ T cells in small intestinal and cecal LPL (E). 
Data represent n=6-13 mice/group as mean ± SEM from at least two independent 
experiments. P values indicated represent a nonparametric Kruskal-Wallis test (D) and a 
unpaired Student’s t test (C, D, E) *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 0,0001. 
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We observed that regardless of infection state in SFB colonized eSPF mice, 
small intestinal LPLs nearly 100% of IL-17A+IL-22- cells were effector 
memory (CD44+CD62L-) cells and around 70% of them expressed CCR6 
when compared to IL-17A-IL-22- cells (Figure 3.7C, 3.7D). Strikingly, after S. 
Tm. infection, in cecal LPLs of SFB colonized eSPF mice IL-17A+IL-22+, IL-
17A+IL-22- and IL-17A-IL-22+ cells demonstrated a similar effector memory 
like state as small intestinal IL-17A+IL-22- cells (Figure 3.7D). Notably, fewer 
IL-17A-IL-22+ CD4+ T cells expressed CCR6 compared to other cytokine 
releasing cell subsets in cecum. These findings were further corroborated by 
isolation and characterization of the LPLs from GF mice monocolonized with 
SFB (Figure 3.8A).  
 
 
Figure 3.8 Characterization of SFB induced CD4+ T cells in GF mice using 
surface markers. 
(A-B) LPL were isolated during steady state and 20h after S.Tm. infection from IL-17AGFP IL-
22BFP FoxP3RFP mice harboring GF or GF+SFB. Percentages of cytokine producing cells 
expressing distinct surface markers i.e. CD44hiCD62L- (Effector memory), CCR6 or 
CD44loCD62L+ (naïve) in small intestine during baseline, in small intestine and cecum during 
S.Tm. infection (A). Enrichment of Vβ14 TCR in IL-17A and IL-22 producing CD4+ T cells 
compared to non-cytokine producing CD4+ T cells in small intestinal and cecal LPL (B). Data 
represent n=5-13 mice/group as mean ± SEM from at least two independent experiments. P 
values indicated represent a nonparametric Kruskal-Wallis test (A) and a unpaired Student’s t 
test (B) *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 0,0001. 
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It has been demonstrated that SFB-induced Th17 cells are specifically 
enriched in the Vβ14 chain of the TCR 17. We therefore monitored Vβ14 TCR 
enrichment in distinct cytokine producing cells after S. Tm. infection. In line 
with the previous reports, small intestinal IL-17A+ (Th17) cells were 
significantly enriched with Vβ14 TCRs compared to Foxp3+ CD4+ T cells 
(Figure 3.7E). In cecal LPLs from SFB colonized eSPF mice infected with S. 
Tm., significant increase in the Vβ14 TCR enrichment was observed 
specifically in IL-17A-IL-22+ and IL-17A+IL-22+ CD4+ T cells compared to IL-
17A+IL-22- and Foxp3+ CD4+ T cells (Figure 3.7E). We performed similar 
experiments in SFB monocolonized GF mice and could show increase in 
Vβ14 TCR enrichment in different CD4+ T cell subsets similar to that 
observed in eSPF+SFB mice (Figure 3.8B). Unlike in eSPF+SFB mice 
increased Vβ14 TCR enrichment was also observed in IL-17A+IL-22- CD4+ T 
cell subset in cecal LPLs after S. Tm. infection (Figure 3.8B).  
 
 
Figure 3.9 SFB modulation of in-vivo CD4+ T cells expressing distinct 
transcription factors. 
LPL were isolated during steady state and 20h after S.Tm. infection from cecal tissues of 
RORγtGFP FoxP3RFP mice harboring eSPF or eSPF+SFB. Representative FACS plots and 
percentages and absolute numbers of CD3+CD4+ cells expressing RORγt and Foxp3. Data 
represent n=6-13 mice/group as mean ± SEM from at least two independent experiments. P 
values indicated represent a unpaired Student’s t test *p < 0,05; **p < 0,01; ***p< 0,001; 
****p< 0,0001. 
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Transcription factor RORγt plays critical role for differentiation of Th17 cells. 
We postulated that SFB primed CD4+ T cells already seed the cecal lamina 
propria and obtain effector function of IL-17A and/or IL-22 secretion after 
Salmonella infection. In order to investigate the existence of in vivo precursor 
for distinct cytokine producing CD4+ T cells we obtained previously described 
RORγtGFPFoxP3RFP reporter mice 18 and rederived them under eSPF 
microbiota condition. Indeed, analysis of CD3+CD4+ cecal LPL revealed 
significantly increased frequencies and numbers of RORγt+ cells in SFB 
colonized eSPF mice (Figure 3.9A). Although Salmonella infection did largely 
not affect the frequencies of RORγt+ cells, the absolute numbers were much 
higher in mice harboring SFB indicating enhanced differentiation of these cells 
(Figure 3.9A). Previous works demonstrated influence of microbiota 
specifically SFB on RORγt+Foxp3+ and Foxp3+ CD4+ T cells 19,20. However, 
in our eSPF facility, SFB colonization does not seem to affect these cells 
(Figure 3.9A). These results demonstrate that SFB colonization results in the 
presence of resting RORγt+CD4+ T cells in cecal lamina propria and during 
early infection with Salmonella pathogen SFB-specific CD4+ T cells 
differentiate to produce IL-17A and/or IL-22.  
 
3.4.4 Bystander activation of SFB-dependent IL-17A and/or IL-22+ CD4+ 
T cells have distinct gene-expression profile 
 
Next we wanted to characterize the detailed transcriptomic profile of distinct in 
vivo cytokine producing cells comparing antigen-specific and bystander 
activation by sorting these cells based on their cytokine expression directly 
from in vivo. From SFB colonized eSPF mice, we FACS sorted 5 distinct 
population of CD3+CD4+ T cells: IL-17A+IL-22- cells from small intestinal 
LPLs of uninfected mice as well as IL-17A+IL-22- T cells from small intestinal 
LPLs, IL-17A+IL-22-, IL-17A-IL-22+ and IL-17A+IL-22+ cells from cecal LPLs 
of S. Tm. infected mice (Figure 3.10A). 
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Figure 3.10 Characterization of SFB induced CD4+ T cells in eSFP mice 
using RNA-seq. 
Small intestinal and cecal CD3+CD4+ LPL were FACS sorted based on their expression of 
IL-17A and/or IL-22 (A). Real time qPCR was performed to validate and confirm the purity of 
FACS sorted cells using specific primers to detect Il17a, Il22 (B).  
(C-E) RNA-seq analysis of FACS sorted cells was performed. Analysis of β-diversity (PCoA) 
of distinct cell subsets based on their transcriptome profile (C). Heatmap shows quantification 
of RNA reads for normalized all differentially expressed gene sets (D) and differential 
expression of specific cytokines and transcription factors (C) among the groups. Data 
represent n=2-4 sample/group. 
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Minimum duplicates of 1000 cells with distinct properties were sorted and low-
input RNAseq was performed according to the protocol describe in method 
section. The purity of different subsets of FACS sorted cells was confirmed 
using specific qPCR for Il17a and Il22 gene expression (Figure 3.10B). 
Interestingly, analysis of β-diversity of transcriptome data using PCoA 
revealed that IL-17A+IL-22- CD4+ T cells from small intestine clustered 
together regardless of infection state (Figure 3.10C). Analysis of global gene 
expression of these two groups also demonstrated similar gene expression 
signatures (Figure 3.10D). Strikingly, IL-17A-IL-22+ and IL-17A+IL-22+ CD4+ 
T cells from infected cecal LPLs clustered together and demonstrated distinct 
gene expression profile from that of small intestinal IL-17A+IL-22- cells 
(Figure 3.10C, 3.10D). IL-17A+IL-22- CD4+ T cells from cecal tissue 
demonstrated unique properties of completely separate clustering in PCoA 
analysis and unique gene expression signature (Figure 3.10C, 3.10D). Next, 
we focused on identifying specific differences in terms of distinct cytokine and 
transcription factor expression among the groups. To our surprise, we 
observed alterations in expression of Ifnγ and Il17f. In contrast to IL-17A+IL-
22- cells from all conditions IL-17A-IL-22+ and IL-17A+IL-22+ cells expressed 
significantly higher Ifnγ and Il17f (Figure 3.10E). Strikingly, Il17f expression 
was highest in IL-17A+IL-22+ CD4+ T cells (Figure 3.10E). A small increase 
in Tnf and Il2 expression was observed in small intestinal IL-17A+IL-22- cells 
(Figure 3.10E). Notably, we did not detect any major differences in expression 
of different transcription factors among these groups. Small intestinal T cells 
expressed somewhat higher Gata3, Rorc and Ahr, whereas cytokine-
producing cells derived from cecum showed higher Tbx21 expression (Figure 
3.10E). Interestingly, strong Foxp3 expression was monitored from cecal IL-
17A+IL-22- cells suggesting that this fraction contains regulatory T cells 
(Figure 3.10E). To confirm our observation regarding discrepancies on Ifnγ 
and Il17f expression, we performed gene-specific qPCR on in vivo FACS 
sorted cells. In line with the transcriptome data, we observed high expression 
of Ifnγ and Il17f in IL-17A-IL-22+ and IL-17A+IL-22+ CD4+ T cells (Figure 
3.11A).  
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Figure 3.11 Validation of RNA-seq results in cytokine knock-in reporter mice. 
Real time qPCR was performed to validate Il17f and Ifnγ expression in FACS sorted cells 
from Figure 10A (A).  
LPL were isolated from cecum during 20h after S.Tm. infection from IL-17AGFP IL-22BFP 
FoxP3RFP eSPF and eSPF+SFB or GF and GF+SFB mice. Percentage of CD3+CD4+IL-
17A+IL-22- cells expressing Foxp3 was measured (B).  
LPL were isolated from cecum of IL-17AGFP IFN-γKatushka FoxP3RFP mice harboring eSPF or 
eSPF+SFB. Representative FACS plots and percentages and absolute numbers of 
CD3+CD4+ cells producing IL-17A and/or IFNγ (C). 
LPL were isolated from cecum of IL-17AGFP IL-22BFPIFN-γKatushka FoxP3RFP mice harboring 
eSPF or eSPF+SFB. Percentage and numbers of different IL-17A and/or IL-22 producing 
CD3+CD4+ cells demonstrating in-vivo IFNγ expression (D).  
Data represent n=2-20 mice/group as mean ± SEM from at least two independent 
experiments. P values indicated represent a unpaired Student’s t test *p < 0,05; **p < 0,01; 
***p< 0,001; ****p< 0,0001. 
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SFB modulation of IFNγ producing CD4+ T cells (Th1) from the previous 
works was inconsistent; from no influence of SFB to induce Th1 to SFB 
modulated strong Th1 response 9,21 . Using cytokine knock-in reporter mice 
we aimed to monitor the effect of SFB on in situ IFNγ producing cells. 
Therefore we obtained previously described IL-17AGFP IFN-γKatushka FoxP3RFP 
mice 22 and rederived them on eSPF microbiota background. Indeed, during 
early stage of Salmonella infection IL-17A+IFNγ+ CD4+ T cells from cecal 
LPLs were significantly increased in SFB colonized eSPF mice (Figure 3.11C) 
suggesting SFB modulation of a unique subset of CD4+ T cells producing 
multiple cytokines i.e. IL-22, IL-17A, IFNγ in infected tissues. There were no 
significant differences in CD4+ T cells producing only IFNγ in presence or 
absence of SFB (Figure 3.11C). However, to confirm generation of in vivo 
multiple cytokine producing cells modulated by SFB we crossed our two 
reporter mouse lines to create novel quadriple IL-17AGFP IL-22BFP IFNγKatushka 
Foxp3RFP reporter mice. Isolation of LPL from Salmonella infected cecal tissue 
revealed significant increase in IFNγ production by IL-17A and IL-22 both 
single and double producing CD4+ T cells in SFB colonized eSPF mice 
(Figure 3.11D). Specifically, similar to the findings from transcriptome 
analysis, the highest production of IFNγ were from IL-17A-IL-22+ and IL-
17A+IL-22+ CD4+ T cells (Figure 3.11D). Since transcriptome analysis 
revealed significant Foxp3 expression by IL-17A+IL-22- CD4+ T cells in 
Salmonella infected cecal LPLs we measured the Foxp3 expression in our in 
vivo isolated LPLs from cytokine reporter mice. Indeed, after Salmonella 
infection only IL17+IL-22- CD4+ T cells present in cecum demonstrated 
increased Foxp3 expression (data not shown). Interestingly, IL17+IL-22- 
CD4+ T cells from SFB deficient mice had significantly higher frequencies of 
Foxp3+ cells compared to that from SFB colonized both eSPF and GF mice 
(Figure 3.11B). Together, these data illustrate distinct properties of SFB-
induced bystander activated cells and suggest that innate CD4+ T cells 
modulated by SFB after enteropathogen infections are able to play unique 
function of multiple cytokine secretion to combat the infection.  
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3.4.5 SFB colonization reduces growth of Salmonella in local tissue 
 
 
Figure 3.12 Colonization of wild type (WT) Salmonella in intestinal tissues 
and content in eSFP mice. 
eSPF and eSPF+SFB mice were infected with S. Tm. wild-type. Body weight of infected mice 
is shown (A). WT Salmonella infected mice were sacrificed 2 days p.i. and S. Tm. CFUs were 
determined in tissue (A) and content (B) of small intestine, cecum and colon. Data represent 
n=5-8 mice/group as mean ± SEM from at least two independent experiments. P values 
indicated represent a unpaired Student’s t test *p < 0,05; **p < 0,01; ***p< 0,001; ****p< 
0,0001. 
 
SFB has been demonstrated to enhance resistance against C. rodentium 
infection 9, however, whether it regulates susceptibility to Salmonella 
colonization in the lumen or tissue invasion is not known. To test whether SFB 
colonization affects Salmonella infection, we employed the antibiotic-induced 
gastroenteritis model and infected eSPF and eSPF+SFB mice with WT 
Salmonella. Overall body weight loss after Salmonella infection did not differ 
in presence or absence of SFB (Figure 3.12A). Hence, we wanted to 
investigate whether presence of SFB in the intestinal microbial community can 
provide any colonization resistance against Salmonella growth and invasion 
into intestinal content and tissue. We detected similar number of Salmonella 
CFUs growing in the gastrointestinal tissue and lumen of both SFB colonized 
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and control eSPF mice 2 days post infection (Figure 3.12A, 3.12B). This 
demonstrates that SFB-induced alterations in the immune system are not able 
to significantly restrict WT Salmonella.  
 
 
Figure 3.13 Colonization of ΔAroA Salmonella mutant in intestinal tissues 
and content in eSPF mice. 
eSPF and eSPF+SFB mice were infected with S. Tm. ΔAroA mutant. Body weight of infected 
mice is shown (A). ΔAroA Salmonella infected mice were sacrificed 2 days p.i. and S. Tm. 
CFUs were determined in tissue (A) and content (B) of small intestine, cecum and colon. LPL 
were isolated 20h after ΔAroA S.Tm. infection from cecum of IL-17AGFP IL-22BFP FoxP3RFP 
mice harboring eSPF or eSPF+SFB. Percentages of IL-17A and/or IL-22 production of distinct 
cell subsets are shown (C). Data represent n=6-16 mice/group as mean ± SEM from at least 
two independent experiments. P values indicated represent a unpaired Student’s t test *p < 
0,05; **p < 0,01; ***p< 0,001; ****p< 0,0001. 
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Notably, Salmonella can expand in the tissues of infected C57Bl/6 mice 
because these mice carry a spontaneous mutation in the Nramp1 gene 23, 
which impairs immune control significantly. Hence, we hypothesized that an 
attenuated strain of Salmonella with a decreased ability for systemic infection 
but still being able to elicit local infection might be affected by the presence of 
SFB-induced immune responses. Therefore, we infected eSPF and SFB 
colonized eSPF mice with a S. Tm strain lacking the aroA gene (ΔaroA) and 
subsequently monitored pathogen colonization 24. Similar to that of WT S. 
Tm., infection with ΔaroA S. Tm. also did not demonstrate any difference in 
body weight loss in presence or absence of SFB (Figure 3.13A). Strikingly, 
despite of similar colonization in the intestinal content, presence of SFB 
resulted in reduced colonization of the Salmonella mutant in the cecal tissue 2 
days post infection (Figure 3.13A, 3.13B). Next, we wanted to confirm whether 
SFB-induced immunomodulatory effects were retained after infection with 
mutant S. Tm. Isolation of LPL from ΔaroA mutant S. Tm. infected mice 
revealed comparable SFB-dependent innate-like cytokine responses from 
CD3+CD4+ T cells as in WT S. Tm. infected mice. Specifically, significant 
increase in both IL-17A and IL-22 production by CD3+CD4+ T cells from cecal 
tissue of SFB colonized mice was observed (Figure 3.13C). Finally, this data 
demonstrated that, SFB modulated bystander activation of CD4+ T cells is 
associated with local protection from pathogen colonization during S. Tm. 
infection. 
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3.5 Discussion 
 
Understanding the contribution of specific members of the microbiota on 
immune homeostasis and inflammation has emerged as central question in 
many physiological and inflammatory processes including mucosal infections. 
In this study we demonstrate that a specific member of intestinal microbiota, 
SFB, can induce differentiation of Th17 and Th22 subsets, which upon 
infection induce proinflammatory and anti-microbial cytokines after bystander 
activation. Furthermore, we identified that the presence of bystander activated 
SFB-specific CD4+ T cells is associated with decreased Salmonella invasion 
into intestinal tissue. 
In the GI tract, IL-17A and IL-22 have shown to contribute to immune 
protection against Helicobacter pylori, Citrobacter rodentium and S. 
Typhimurium 25–29. These cytokines are produced by distinct subsets including 
Th17 and Th22 cells. Several studies have provided strong evidence of 
plasticity for these cell lineages both in vivo and in vitro depending on types of 
inflammation and culture conditions respectively 30–32. Such plasticity of 
acquiring functional characteristics of other cell subsets i.e. secretion of non-
canonical cytokine like IFNγ or IL-10 may play crucial role during specific 
inflammatory disease conditions. Therefore it is important to understand in 
vivo functional properties of these cell subsets under specific inflammatory 
condition. In the GI tract commensal microbiota shapes the intestinal immune 
system by regulating T helper (Th) cell lineage differentiation. For example, 
Bacteroides fragilis monocolonization not only establishes proper systemic 
Th1/Th2 balance, but also can induce regulatory T (Treg) cell differentiation in 
the gut 33,34. In addition, SFB facilitate the development of Th17 cells in the 
small intestine or a mixture of 17 strains within clusters IV, XIVa, and XVIII of 
Clostridiales isolated from human feces can also induce the differentiation and 
expansion of Treg cells in the colon 35. Recent studies have also 
demonstrated an effect of the gut microbiota on CD4 T cell during intestinal 
inflammation 12. However, it is not clear whether antigen-specific classical 
CD4+ T cells are distinct from bystander-activated cells in vivo and which 
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specific member of the intestinal microbiota is responsible to induce such 
bystander activation of immune cells.  
To investigate the diversity of intestinal CD4+ T cell responses directly from in 
situ using gene expression analysis have several caveats. First, subsets are 
largely distinguished by expression of transcription factors and cytokine 
expression. These can be assessed using antibodies and flow cytometry, but 
require fixation of the cell precluding the isolation of RNA. To allow isolation of 
cytokine-producing cells, so-called capture assays have been developed but 
these require restimulation of the cells ex vivo, which impacts their gene 
expression profiles. Finally, these cells are typically present in relatively low 
numbers complicating their analysis. To overcome these limitations, several 
groups have developed transgenic mouse lines, in which the expression of a 
fluorescent protein is under control of the endogenous promoter of a 
transcription factor or cytokine. These mouse lines allow the isolation of 
transcription factor or cytokine-positive cell ex vivo based on the expression of 
individual or combinations of fluorescent proteins 36. In our study, we have 
employed two lines of mice allowing i) the identification of Foxp3 and Rorγt 
expressing cells (RorγtGFPFoxp3RFP) and ii) the identification of Foxp3, IL-17A, 
IL-22 and IFN-γ expressing cells (IL-17AGFP IL-22BFP Foxp3RFP; IL-17AGFP IFN-
γKatuska Foxp3RFP). 
Using our novel transgenic reporter mice we could demonstrate that at early 
stage of Streptomycin-pretreated S. Typhimurium infected mice memory 
CD4+ T cells are the major source of IL-17A and IL-22 cytokine production. In 
line with previous work, we could observe an increase in the number of these 
innate-like types of IL-17A+IL-22- and IL-17A+IL-22+ CD4+ T cells in cecal 
LPL from infected mice 12. Moreover, we also observed a significant increase 
in the numbers and frequencies in IL-17A-IL-22+ CD4+ T cells. However, in 
steady state condition our finding contrasted previous report of IL-22 reporter 
mice since we did not detect any IL-22 production from intestinal LPLs from 
non-infected mice 37. This may reflect differences in microbiota and diet 
composition in animal colonies, since these factors have been demonstrated 
to modulate IL-22 production. Notably, IL-22 is not detectable in the colonic 
mucosa of healthy human subjects; however, IL-22 expression is readily 
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detectable from CD4+ T cells in the colonic mucosa of IBD patients 38. Studies 
have demonstrated that the frequency of IL-22-producing cells is increased in 
UC patients as well as CD patients, indicating a possible pro-inflammatory 
role in etiology of IBD or an attempt of the cells to contribute to tissue repair 
38,39. To investigate the involvement of specific microbiota modulating such 
innate-like CD4+ T cells we rederived our reporter mice into an eSPF barrier 
lacking many known potential pathobionts i.e. SFB, Helicobacter spp., 
Prevotellaceae, murine Norovirus, and murine protozoa that have previously 
been reported to modulate host adaptive immunity. Strikingly, mice from this 
eSPF barrier completely lost their ability to induce innate IL-17A and IL-22 
producing CD4+ T cells upon Salmonella infection and cytokine production 
ability was successfully restored upon SFB colonization. We could also 
demonstrate that at early stages of Salmonella infection SFB can also induce 
CD4+ T cells producing only IL-22, which to our knowledge is the first report 
to observe microbiota modulation of Th22 cells. Unlike earlier studies that 
relied on ex vivo restimulation SFB colonization did not show any in vivo IL-22 
producing Th17 cells at baseline, rather only classical IL-17A producing Th17 
were observed in small intestinal LPLs. In line with previous findings, 
transcription factor knock-in reporter mice (RorγtGFPFoxp3RFP) showed 
RORγt+ Th17 cells were already present at baseline in SFB colonized cecal 
LPLs. Moreover, specificity of these innate IL-17A and IL-22 producing CD4+ 
T cells to SFB was confirmed since these cells expressed significantly higher 
Vβ14 TCR that is previously described as SFB-specific TCR 17. Together 
these findings suggest that in vivo SFB is not only essential to induce steady-
state Th17 cells in the small intestine, but also provide signals resulting in the 
development of CD4+ T cell subsets characterized by the ability to produce 
IL-22 and IL-17A cells rapidly after infection in the intestine. 
To further characterize SFB-induced innate-like CD4+ T cells we employed 
transcriptional profiling of these distinct cell subsets directly isolated from 
intestinal LPLs based on their cytokine secretion. Strikingly, IL-17A+IL-22+ 
CD4+ T cells isolated from S. Tm infected mice demonstrated distinct gene 
expression profiles compared to Th17 cells isolated from the SI of SFB 
colonized mice at baseline and clustered more closely to IL-22 only producing 
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CD4+ T cells. Strikingly, these differences were mainly due to significant 
increased expression of IFNγ and IL-17F by IL-17A-IL-22+ and IL-17A+IL-22+ 
CD4+ T cells compared to Th17 cells. Increases in IFNγ expression might 
benefit the host via diverse mechanisms such as controlling pathogen loads in 
the intestinal tissue and regulating mucin release by goblet cells or other so 
far unknown effects 40–42. Previous reports regarding the role of SFB to induce 
IFNγ producing CD4+ T (Th1) cells were contradictory demonstrating no Th1 
induction to significant Th1 induction in presence of SFB 9,21. Using different 
cytokine reporter mice we demonstrated a direct influence of SFB on IFNγ 
secretion from only IL-17A and/or IL-22 producing CD4+ T cells, but not from 
IL-17A-IL-22- CD4+ T (classical Th1) cells. Analysis of transcription factors 
revealed only a minor increase in Tbx21 expression in these innate like CD4+ 
cells compared to classical Th17 cells. Detailed studies regarding the 
transcriptional regulation of these specific Th cell subsets are still necessary. 
After oral infection with wild type S. Tm. SFB colonization did not enhance 
pathogen clearance. However, increased numbers of multifunctional innate 
like CD4+ T cells induced by SFB significantly enhanced clearance of ΔAroA 
mutant of S. Tm from local tissue. This suggests SFB induced 
immunomodulatory effects in the GI tract are only able to provide protection 
from enteropathogen invasion locally. Further studies are needed to observe 
whether co-colonization of SFB with some other intestinal microbiota having 
immunomodulatory effects may synergize the protective effects against 
systemic enteropathogen infection. 
In conclusion this study allowed us to quantitatively assess the effect of de 
novo colonization of intestinal commensal bacteria on CD4+ T cell 
differentiation in vivo using gnotobiotic mice and to establish gene signatures 
distinguishing regulatory and inflammatory CD4+ T cell subsets based on 
their induction route. We believe that this knowledge will eventually allow 
identifying the sources of pathogenic memory cells that alter disease 
susceptibility upon by-stander activation during inflammatory responses. 
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CHAPTER 4 
 
General Discussion and Outlook 
 
The gastrointestinal (GI) tract of vertebrates is densely colonized by complex 
and dynamic ecosystems consisting of hundreds of species of bacteria as well 
as archaea, viruses and parasites, commonly referred to as the gut microbiota 
1. These complex ecosystems have coevolved together with the host to 
maintain a mutualistic partnership 2,3. Altogether, these microorganisms 
contribute to various essential physiological functions such as the metabolism 
of complex dietary ingredients, resistance against colonization of pathogen 
and proper development of the host’s immune system. Specifically, bacteria 
have been in the focus of numerous studies, since they and their metabolic 
output represent the largest and most diverse proportion of these 
communities 4,5. The advent of culture independent high-throughput DNA 
sequencing technologies enabled scientists to better classify and characterize 
the composition of the microbiota. This has led to the realization that in the gut 
the composition of the microbiota can vary greatly among individuals and it is 
highly susceptible to change with genetic predisposition or altered 
environmental factors for instance, diet, antibiotic use, influx or efflux of other 
microbes 6. Moreover, diverse disease conditions have been associated with 
imbalances in the composition of gut microbiota, a state now commonly 
referred to as dysbiosis 7–9. While experimental confirmation is still awaited in 
many pathophysiological conditions, based on findings in a number of 
diseases it is considered highly probable that differences in community 
structure and function can actively influence the outcome of many different 
types of immunological, metabolic and even neurological diseases. Therefore, 
the understanding of the homeostatic balance in the intestinal microbiota and 
the crosstalk with the host is crucial to maintain and promote human health. 
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In the GI tract inflammatory diseases caused by infectious and environmental 
agents as well as misguided immune responses are the most common forms
 of GI disorders 10–12. In the broader sense, the inflammation associated with 
these conditions is a complex biological response, in which the immune 
system attempts to neutralize or eliminate injurious stimuli and eventually 
allow regeneration and healing. Specifically, while the primary role of this 
inflammatory response is to assist host defense, inflammation can cause 
substantial collateral damage when over-activated or not properly terminated. 
Moreover, whether a specific component of the inflammatory response will be 
beneficial or harmful is dependent on types of stimuli, environmental factors 
and host immune status. An important part of the inflammatory processes are 
diverse types of immune cells including different innate immune cells, e.g. 
macrophage, monocyte, dendritic cells, and neutrophils as well as adaptive 
immune cells, e.g. T cells and B cells. Different and sometimes overlapping 
cell subsets secrete immunomodulatory proteins, called cytokines, which are 
involved in the modulation of inflammation, e.g. interleukin (IL)-1, IL-6, and 
TNF-α. The important role of some of the cytokines in immune-mediated 
diseases is demonstrated by improved patient well-being after their 
neutralization to minimize inflammation. The intestinal microbiota, strongly 
involved in homeostatic maturation and education of the host immune system 
has also been associated regulating different inflammatory conditions in GI 
tract as well as extra-intestinal inflammatory disorders. However, whether 
microbiota is directly involved in exerting inflammation and whether 
inflammatory responses modulated by the microbiota are beneficial or harmful 
remains to be elucidated in detail. Hence, understanding if and how exactly 
the microbiota modulates intestinal inflammation may help clinicians to 
develop better and more specific therapeutics for gastrointestinal diseases. 
The overall aim of the thesis was to characterize the interplay of the hosts 
immune system with specific model gut microbial communities (chapter 2) and 
a distinct immunomodulatory commensal (chapter 3) assessing the effect on 
modulating GI inflammation and to identify distinct in vivo host immune 
response influenced by them.  
 
Chapter 4 
 
 
 125 
In the first part of the thesis, we studied a mouse model of inflammatory bowel 
disease (IBD), which includes a diverse group of immune-mediated diseases 
in the GI tract. A common characteristic of IBD is damage to the intestinal 
barrier that during homeostasis serves as critical barrier to separate the 
intestinal microbiome from the host’s immune system 13. Damage to the 
intestinal barrier can be modeled in the mouse using the chemical dextran 
sodium sulphate, which induces barrier damage and subsequently 
inflammation in response to the microbiota. We demonstrate that alterations in 
the microbiota result in different susceptibilities to DSS colitis. IBD in human 
patients has been associated with decrease in overall diversity of the 
intestinal microbial communities and overgrowth of the phyla Proteobacteria 
over resident Firmicutes and Bacteroides 14. Notably, we demonstrated that 
lowered Firmicutes / Bacteroides ratios occurred in all microbial communities, 
which were able to enhance colitis susceptibility. Specifically, colitogenic 
community derived from Nlrp6 inflammasome deficient mice showed lowest 
ratio of Firmicutes / Proteobacteria. Both innate and adaptive arm of immune 
system play crucial role to develop IBD 15. We investigated whether a 
common theme, lowered Firmicutes / Bacteroides ratios, enhanced colitis 
development via shared or distinct immune pathways. However, this was not 
true. Overexpansion of phyla Proteobacteria demonstrated generation of 
pathogenic CD4+ T cells with ability to secret distinct proinflammatory 
cytokines i.e. IL-17A and IFNγ. In contrast, another colitogenic community 
only with over expanded Bacteroides phyla could develop colitis already in 
absence of adaptive immunity and demonstrated significant infiltration of 
neutrophils and associated chemokines and higher TNFα. Therapeutic 
strategies targeting proinflammatory cytokines are commonly used in IBD 
patients 16. However, anti-cytokine therapies (such as antibodies specific for 
TNF, IL-12 or IL-23) and cytokine signaling blockers (such as tofacitinib) only 
seem to have beneficial clinical effects in certain subgroups of patients 17–19. 
Variability in microbiota composition among patients may reflect such 
differences in efficacy of therapies. Our data suggesting a microbiota 
dependent pathway of disease development indicate careful investigation of 
IBD patients to identify specific microbiota communities or microbiota-induced 
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immune effectors as biomarkers may help clinicians to develop personalized 
IBD therapy.  
 
Targeting or manipulating a broad intestinal microbial community may disrupt 
normal homeostatic balance. Therefore, identifying single bacterial species 
modulating specific host immune pathway involved in enhancing or mitigating 
inflammation may be associated with less unwanted side-effects. We hence 
extended our investigation to characterize the effect of specific intestinal 
microbial species on the immune system. We focused on segmented 
filamentous bacteria (SFB), a commensal present in both colitogenic 
communities. SFB intimately attaches to the intestinal epithelial cells and is 
known to induce distinct host immune responses including IgA 20, Th17 cells 
21 and Treg 22 induction. In different models of intestinal and extra-intestinal 
immune-mediated inflammatory diseases SFB has been reported to 
exacerbate inflammation 23–25. However, SFB has also shown to provide 
enhanced resistance against intestinal inflammation caused by Citrobacterium 
rodentium 21. We therefore wanted to investigate whether SFB alone can 
exert beneficial in vivo host immune response and protection in models of 
intestinal enteropathogen infection. Using a mouse model of Salmonella 
induced gastroenteritis we demonstrated that SFB alone could specifically 
induce distinct subsets of CD4+ T cells with the ability to secret multiple 
immunomodulatory cytokines, i.e. IL-17A, IL-17F, IL-22 and IFNγ. These 
cytokines have beneficial effects of providing protection against infection via 
multiple pathways i.e. enhanced antimicrobial peptide secretion, tissue 
regeneration, increased bacterial killing. Indeed, SFB colonization in our 
model enhanced colonization resistance against Salmonella invasion. 
However, whether interaction of SFB with other intestinal components of the 
microbiota can exert synergistic protective effects needs to be investigated in 
future.  
 
Mouse model of human disease are powerful tool to investigate role of host 
immunity and microbiota during both homeostasis and inflammation. 
However, presence of certain variables in the experimental system can affect 
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reproducibility and interpretation of the results. Studies have shown that 
microbiota composition in the same mouse lines from different facilities 26–28, 
or even within one facility 29 can vary significantly and such variability has 
resulted in different outcomes. As an example, possible contradictions in 
studies on Toll-like receptor 5 (TLR5) influencing intestinal microbiota 
compositions were largely due to husbandry history rather than genotype 30. 
Hence, throughout our entire study we have undertaken careful approach to 
maintain standardized experimental systems to avoid unwanted effects of 
different variables like genotype, environmental factors etc on the murine 
microbiota. Specifically, researchers have focused to obtain standardized 
microbiota models lacking potential pathobionts and then further manipulate 
the microbiota through e.g. cohousing or cross fostering. In this study we have 
employed standardized isobiotic mouse lines in which the microbiota could be 
manipulated at will. Moreover, we ensured genetic background and use of 
germ free mice and cohousing also allowed us to further confirm microbiota 
effect. However, to study direct effect of human microbiota on host immunity, 
besides association studies more sophisticated techniques like humanized 
mouse models need to be employed.  
 
In conclusion, together our studies strongly support the fact that in an 
immune-competent host alteration in microbiota composition alone can 
drastically influence disease pathogenicity. Distinct members of microbial 
species are able to induce CD4+ T cells, however such microbiota modulated 
T cell functionality can be both beneficial or harmful depending on 
inflammatory conditions. Further studies are needed to identify specific 
microbial members inducing pathogenic and beneficial T cell responses in 
host and whether distinct T cell subsets inducing bacterial species can 
interact with each other to influence disease outcome. Moreover, detailed 
metabolic profiling of such immunomodulatory microbiotal species may reveal 
distinct metabolites driving such induction of pathogenic or beneficial T cell 
responses. This may help to target or add certain metabolites during 
inflammatory diseases to obtain similar effects exerted by the microbiota itself.  
 
Chapter 4 
 
 
 128 
Most importantly, similar microbiota induced effects are most likely to be also 
present in human and detailed careful investigation of such complex 
interaction in human subjects may help to identify specific immunomodulatory 
responses provided by human microbiota. Which in turn may help to stratify 
patients according to their microbiotal composition and imply to develop 
personalized therapies targeting microbiota or microbiota induced host 
responses against different inflammatory diseases. 
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